Page last updated: 2024-11-13

mobic

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54677470
CHEMBL ID599
CHEMBL ID1741042
CHEBI ID6741
SCHEMBL ID713100
SCHEMBL ID33369
SCHEMBL ID3576
SCHEMBL ID23589638
MeSH IDM0398523

Synonyms (214)

Synonym
BIDD:GT0726
AB00383033-17
MLS000028587 ,
tenaron
parocin
eti-511
movatec
mobicox
n-1539 ,
metacam
mobic
meloxicamum [latin]
4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
miloxicam
2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-n-(5-methylthiazolyl)-, 1,1-dioxide
4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide
movalis
uh-ac 62xx
4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
SPECTRUM_001633
ccris 9139
c14h13n3o4s2
mobec
LOPAC0_000766
SPECTRUM5_001813
SMP2_000133
HSCI1_000045
MLS001304725
C08169
71125-38-7
meloxicam
DB00814
D00969
meloxicam (jan/usp/inn)
mobic (tn)
NCGC00022924-04
NCGC00022924-03
smr000058994
KBIO2_007249
KBIO3_001477
KBIO2_002113
KBIO2_004681
KBIOSS_002113
KBIOGR_001234
SPBIO_000902
SPECTRUM2_000941
SPECTRUM3_000649
SPECTRUM4_000787
SPECTRUM1504150
BSPBIO_002257
NCGC00018248-01
smr000718800
MLS001306413
AC-1325
HMS2089B18
M1959
AKOS000279442
coxicam
contacera
meloxidyl
flexicam
revitacam
meloxivet
inflacam
meloxidolor
recocam
acticam
melfax
CHEMBL599 ,
chebi:6741 ,
emdocam
melosus
uh-ac-62 xx
melovem
n1539 ,
uhac-62xx
loxicom
meloxoral
rheumocam
HMS1922D19
4-hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
4-hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
bdbm50056998
A837087
(3z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
(3z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one
NCGC00018248-04
NCGC00018248-03
NCGC00018248-05
NCGC00018248-02
NCGC00018248-06
HMS3259H06
HMS2096I19
3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2h-1lambda6,2-benzothiazine-1,1,4-trione
EN300-52507
tox21_302756
NCGC00256316-01
dtxsid1020803 ,
dtxcid70803
cas-71125-38-7
tox21_113192
NCGC00259238-01
tox21_111734
tox21_201689
4-hydroxy-2-methyl-n-(5-methylthiazol-2-yl)-2h-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
HMS2236C09
HMS2234P07
vg2qf83cgl ,
meloxicam [usan:usp:inn:ban]
unii-vg2qf83cgl
vivlodex
coxflam
hsdb 7741
revmoksikam
meloxicamum
melonex
CCG-39098
FT-0628193
NCGC00018248-08
anjeso
meloxicam [ema epar veterinary]
meloxicam [usp monograph]
meloxicam [usan]
meloxicam [inn]
meloxicam [mi]
meloxicam [vandf]
zeleris component meloxicam
meloxicam [orange book]
meloxicam [green book]
meloxicam component of zynrelef
meloxicam [ep monograph]
meloxicam component of zeleris
zynrelef component meloxicam
meloxicam [usp-rs]
meloxicam [hsdb]
meloxicam [who-dd]
qmiiz odt
meloxicam [mart.]
meloxicam [jan]
S1734
HMS3372C13
4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
HMS3372P18
gtpl7220
HY-B0261
SCHEMBL713100
AB00383033-18
4-hydroxy-2-methyl-n-(5-methy-2-thiazolyl)-2h-1,2-benzothiazine-3-caboxamide-1,1-dioxide
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
MLS006011422
NC00698
SCHEMBL33369
SCHEMBL3576
tox21_111734_1
NCGC00263878-02
KS-1084
AN-668/13244001
F2173-0387
CHEMBL1741042
Z1695493323
meloxicam (mobic)
(e)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4h-benzo[e][1,2]thiazin-4-one 1,1-dioxide
OPERA_ID_2
AB00383033_20
mfcd00868752
4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
AKOS026749959
HMS3655K06
2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-, 1,1-dioxide
meloxicam 1.0 mg/ml in dimethyl sulfoxide
SR-01000003132-10
133687-22-6
HMS3713I19
SW219562-1
NCGC00018248-07
Q414028
meloxicam - cas 71125-38-7
F20356
meloxicam,(s)
meloxicam 100 microg/ml in acetonitrile
BCP11928
NCGC00018248-23
(3e)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1lambda6,2-benzothiazin-4-one
HMS3884G08
AMY40407
HMS3744K09
NCGC00018248-26
2h-1,2-benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-, 1,1-dioxide
4-hydroxy-2-methyl-n-(5-methyl-2-thiazole)-2h-1,2-benzothiazine-3 -carboxamide 1,1-dioxide
NCGC00018248-25
NCGC00018248-10
meloxicam 1000 microg/ml in acetonitrile
SCHEMBL23589638
meloxicam impurity standard
BH164661
4-hydroxy-2-methyl-n-(5-methylthiazol-2-yl)-2h-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide
meloxicam (usan:usp:inn:ban)
metacam oral suspension
meloxicam (ema epar veterinary)
meloxicam injection
orocam transmucosal oral spray
meloxicam (usp-rs)
ostilox
meloxicam (usp monograph)
meloxicam (mart.)
metacam 5 mg/ml solution for injection
4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
m01ac06
meloxicamum (latin)
alloxate
4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benothiazine-3-carboxamide 1,1-dioxide
meloxicam solution for injection
meloxicam (ep monograph)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Meloxicam was better tolerated in the gastrointestinal (GI) tract, with fewer GI adverse events in the meloxicam-treated group (30."( A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis.
Barceló, P; Bevis, PJ; Bluhmki, E; Distel, M; Le Loët, X; Schattenkirchner, M; Wojtulewski, JA, 1996
)
0.29
" Twenty-eight per cent of patients experienced gastrointestinal (GI) adverse events, 21% musculoskeletal system disorders, 18% skin disorders and 15% respiratory disorders."( A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis.
Bluhmki, E; Degner, FL; Ghozlan, R; Huskisson, EC; Kurthen, R, 1996
)
0.29
" The type and frequency of adverse events were comparable for the two drugs."( A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.
Bluhmki, E; Distel, M; Lindén, B, 1996
)
0.29
" The most common adverse events were GI complaints of abdominal pain and dyspepsia."( An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment.
Bevis, PJ; Bird, HA; Lapham, G, 1996
)
0.29
" This paper presents a global safety analysis of data from meloxicam clinical studies, focusing on gastrointestinal (GI) adverse events."( Safety of meloxicam: a global analysis of clinical trials.
Bluhmki, E; Distel, M; Fries, J; Mueller, C, 1996
)
0.29
" This finding was supported by the low incidence of adverse events."( Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis.
Bevis, PJ; Bluhmki, E; Distel, M; Prouse, PJ,
)
0.13
" Piroxicam and meloxicam suppositories were equally well tolerated, with no serious adverse events recorded in either treatment group."( A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study.
Angelini, M; Carrabba, M; Cigarini, P; Galanti, A; Marini, MG; Paresce, E, 1995
)
0.29
" Adverse effects include gastrointestinal and renal irritation such as nausea, vomiting and hemorrhagic gastroenteropathy."( [Observations on the side effects after application of non-steroidal anti-inflammatory agents in dogs].
Gassner, G; Schütt-Mast, I; Stephan, I, 1998
)
0.3
" Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy."( Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998
)
0.3
" The incidence of adverse events was significantly lower in the meloxicam group (22."( Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998
)
0.3
"This article provides a systematic review of the frequency and severity of adverse gastrointestinal (GI) events among patients using meloxicam, a cyclooxygenase (COX)-2-selective nonsteroidal anti-inflammatory drug (NSAID)."( Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
Schoenfeld, P, 1999
)
0.3
"Meloxicam is a novel nonsteroidal anti-inflammatory drug (NSAID) which may be associated with fewer adverse upper gastrointestinal events than other NSAIDs because it preferentially inhibits the inducible enzyme cyclo-oxygenase-2 relative to the constitutive isoform, cyclo-oxygenase-1."( The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.
Biswas, P; Mann, RD; Martin, RM, 2000
)
0.31
" We sent short questionnaires to all prescribers asking about adverse events experienced within 6 months of the first prescription."( The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.
Biswas, P; Mann, RD; Martin, RM, 2000
)
0.31
" Safety was assessed by evaluation of adverse events, vital signs, and laboratory data."( Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000
)
0.31
"The incidence of all adverse events was lower at each dosage of meloxicam than for diclofenac but greater than for placebo."( Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000
)
0.31
"Meloxicam is a safe and effective medication for the symptomatic treatment of OA."( Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000
)
0.31
"Paracetamole and codeine are safe alternative analgesics for analgesic intolerant patients."( Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
Kalyoncu, AF; Karakaya, G,
)
0.13
" The better GI tolerability of meloxicam was also suggested by fewer adverse GI events and no withdrawals due to adverse events compared with piroxicam."( Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang, DM; Hsieh, TC; Hsu, CT; Kuo, SY; Young, TH, 2001
)
0.31
"Results suggest that preoperative administration of meloxicam is a safe and effective method of controlling postoperative pain for 20 hours in dogs undergoing abdominal surgery; the analgesic effects of meloxicam were comparable to those of ketoprofen and superior to those of butorphanol."( Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery.
Foster, R; Mathews, KA; McDonell, W; Pettifer, G, 2001
)
0.31
"Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events."( Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
Devière, J, 2002
)
0.31
" No adverse events were reported due to the use of meloxicam."( Investigation on the clinical efficacy and safety of meloxicam (Metacam) in the treatment of non-infectious locomotor disorders in pigs.
Friton, GM; Kleemann, R; Philipp, H; Schneider, T,
)
0.13
"In healthy dogs, meloxicam appears to be safe with regard to adverse effects on the gastrointestinal tract."( Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs.
Boston, SE; Kruth, SA; Moens, NM; Southorn, EP, 2003
)
0.32
"The herein described challenge with alternative drugs, meloxicam and nimesulide, is a safe tool for the management of NSAIDs-intolerant patients."( Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs.
Bonadonna, P; Canonica, GW; Crivellaro, M; Dama, A; Passalacqua, G; Schiappoli, M; Senna, GE, 2003
)
0.32
" One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs."( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004
)
0.32
" All patients with asthma tolerated rofecoxib without any adverse effects."( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004
)
0.32
" Thirty-five subjects presented with gastrointestinal (GI) adverse events (AEs)."( Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea.
Baracat, EC; Barbosa, IC; Bedone, AJ; Camargos, A; Cortes, RJ; de Mello, NR; de Souza, RN; Martinez Alcala, FO; Rumi, DO; Tomaz, G; Velasco, JA, 2004
)
0.32
" Safety parameters were assessed by evaluating the frequency of adverse events in the 3 groups."( A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
Alessio, M; Artamonova, V; Baildam, E; Bandeira, M; Buoncompagni, A; Emminger, W; Falcini, F; Foeldvari, I; Gerloni, V; Hanft, G; Joos, R; Kone-Paut, I; Lenhardt, A; Martini, A; Mouy, R; Nikishina, I; Pachanov, ED; Prieur, AM; Ruperto, N; Schwarz, R; Shachbazian, Y; Sigmund, R; Simianer, S; Zulian, F, 2005
)
0.33
" There were no differences in the frequency of adverse events or abnormal laboratory values between the 3 groups."( A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
Alessio, M; Artamonova, V; Baildam, E; Bandeira, M; Buoncompagni, A; Emminger, W; Falcini, F; Foeldvari, I; Gerloni, V; Hanft, G; Joos, R; Kone-Paut, I; Lenhardt, A; Martini, A; Mouy, R; Nikishina, I; Pachanov, ED; Prieur, AM; Ruperto, N; Schwarz, R; Shachbazian, Y; Sigmund, R; Simianer, S; Zulian, F, 2005
)
0.33
"5 mg of meloxicam is a safe alternative treatment for ASA-hypersensitive asthma and/or NP patients with proven hypersensitivity via oral ASA challenges."( Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study.
Bavbek, S; Dursun, AB; Dursun, E; Eryilmaz, A; Misirligil, Z, 2007
)
0.34
"The identification of a safe and reliable alternative for patients with non-steroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema is a frequent problem for dermatologists and other practitioners."( Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
Chiba, Y; Ikezawa, Z; Inomata, N; Kambara, T; Onoda, M; Osuna, H; Takeshita, Y; Yamaguchi, J, 2007
)
0.34
"To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.34
"Carprofen induced the lowest frequency of gastrointestinal adverse effects, followed by meloxicam."( Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
Basílio, AC; Brandão, CV; Luna, SP; Machado, LP; Moutinho, FQ; Steagall, PV; Takahira, RK, 2007
)
0.34
" Gastrointestinal upset in 2/46 (4%) cats was the only adverse effect noted."( Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats.
Gunew, MN; Marshall, RD; Menrath, VH, 2008
)
0.35
" We demonstrate that both DF and meloxicam are toxic to renal tubular epithelial (RTE) cells following 12 h of exposure, due to an increase in production of reactive oxygen species (ROS), which could be temporarily ameliorated by pre-incubation with uric acid (UA)."( Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction.
Naidoo, V; Swan, GE, 2009
)
0.35
"5 mg meloxicam is a safe alternative for ASA/NSAID-intolerant UR/AE patients."( Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema.
Aydin, O; Bavbek, S; Demirel, YS; Göksel, O; Misirligil, Z, 2010
)
0.36
"Nephrotic syndrome, with or without concomitant tubulointerstitial nephritis, is a rare renal adverse effect of NSAIDs."( Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.
Knotek, M; Ljubanovic, D; Mihovilovic, K, 2011
)
0.37
"To compare the efficacy and adverse effects of sustained-release (SR) buprenorphine following SC administration and buprenorphine following oral transmucosal (OTM) administration in cats undergoing ovariohysterectomy."( Comparison of the efficacy and adverse effects of sustained-release buprenorphine hydrochloride following subcutaneous administration and buprenorphine hydrochloride following oral transmucosal administration in cats undergoing ovariohysterectomy.
Catbagan, DL; Mama, KR; Mich, PM; Quimby, JM; Rychel, JK, 2011
)
0.37
"In cats undergoing ovariohysterectomy, SC administration of a preoperative dose of SR buprenorphine appeared to have comparable efficacy and adverse effect profile as that of twice-daily OTM administration of buprenorphine before and after surgery."( Comparison of the efficacy and adverse effects of sustained-release buprenorphine hydrochloride following subcutaneous administration and buprenorphine hydrochloride following oral transmucosal administration in cats undergoing ovariohysterectomy.
Catbagan, DL; Mama, KR; Mich, PM; Quimby, JM; Rychel, JK, 2011
)
0.37
" Higher doses were associated with dose-dependent adverse effects typical of class of drugs."( Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.
Boston, R; Edwards, S; Lievaart, J; Noble, G; Pippia, J; Raidal, SL,
)
0.13
"COX-2 inhibitors are safe alternatives in patients with cross-reactive non-steroidal anti-inflammatory drug (NSAID) hypersensitivity."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"This study included the retrospective analysis of cases with cross-reactive NSAID hypersensitivity who underwent DPTs with COX-2 inhibitors in order to find safe alternatives."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"Our results suggest to follow the traditional DPT method to introduce COX-2 inhibitors for finding safe alternatives in all patients with cross-reactive NSAID hypersensitivity before prescription as uncertainty of any predictive factor for a positive response continues."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"The pharmacokinetics of meloxicam will be different in foals compared with adult horses, and foals could be at increased risk for adverse drug effects."( Pharmacokinetics and safety of oral administration of meloxicam to foals.
Boston, R; Edwards, S; Noble, GK; Pippia, J; Raidal, SL,
)
0.13
" In contrast to findings for other NSAIDs, foals appeared more resilient to the adverse effects of this drug than was observed in adult horses."( Pharmacokinetics and safety of oral administration of meloxicam to foals.
Boston, R; Edwards, S; Noble, GK; Pippia, J; Raidal, SL,
)
0.13
"Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)."( Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013
)
0.39
" When the possibility of poor compliance and the potential adverse effects of misoprostol are considered, rebamipide appears to be a clinically effective and safe alternative."( Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity.
Cho, CS; Kang, YM; Kim, JH; Kim, SK; Lee, DH; Lee, SK; Lee, ST; Lee, YC; Park, SH; Park, W; Park, YW; Rew, JS; Yoo, WH, 2014
)
0.4
"Nonsteroidal anti-inflammatory drugs (NSAIDs) such as meloxicam are commonly used to treat osteoarthritis (OA) but are associated with potentially serious dose-related adverse events (AEs)."( Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study.
Altman, R; Gibofsky, A; Hochberg, M; Jaros, M; Young, C, 2015
)
0.42
" The use of these drugs causes adverse effects, the risk of which can be minimized."( [Improvement of the efficacy and safety of the treatment of patients with low back pain].
Kamchatnov, PR,
)
0.13
" No difference in adverse events was observed between the two groups."( Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Wang, J, 2018
)
0.48
" Safety assessments included the incidence of adverse events (AEs), physical examinations, laboratory tests, 12-lead electrocardiography, and wound healing."( Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial.
Du, W; Freyer, A; Gottlieb, IJ; Hakakian, F; Keller, R; Mack, RJ; McCallum, SW; Pollak, RA; Zimmerman, JC, 2018
)
0.48
" Both meloxicam and diclofenac exerted toxic effects on the hepatic cells."( The use of liver slices from the Cape vulture (Gyps coprotheres) to better understand the role of liver toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) in vultures.
Adawaren, EO; Bekker, L; Duncan, N; Mukandiwa, L; Naidoo, V; Njoya, EM, 2018
)
0.48
" This study aims to evaluate the effect of resveratrol, as an adjuvant with meloxicam (Mlx), on the pain and functional activity during a 90-day period and monitor the adverse effects on kidney and liver functions, lipid profile, and hematological markers."( Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study.
Ahmmad, RS; Ali, ZS; Hussain, SA; Marouf, BH, 2018
)
0.48
" The clinical and biochemical markers indicated that 500 mg/day of resveratrol, as an adjuvant with Mlx, is safe and well tolerated by the knee OA patients."( Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study.
Ahmmad, RS; Ali, ZS; Hussain, SA; Marouf, BH, 2018
)
0.48
" Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption."( A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery.
Ayad, SS; Bergese, SD; Candiotti, KA; Du, W; Gomez, A; Mack, RJ; Marcet, JE; McCallum, SW; Melson, TI, 2019
)
0.51
" While measured to have a moderate effect on pain in osteoarthritis, NSAIDs have been associated with wide-ranging adverse events affecting the gastrointestinal, cardiovascular, and renal systems."( Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?
Al-Daghri, N; Bruyère, O; Chapurlat, R; Cooper, C; Herrero-Beaumont, G; Rannou, F; Reginster, JY; Roth, R; Uebelhart, D, 2019
)
0.51
" Generally, meloxicam IV was well tolerated, evidenced by the incidence of adverse events compared to placebo and lack of deaths and treatment-related serious adverse events."( Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial.
Du, W; Freyer, A; Mack, RJ; McCallum, SW; Rechberger, T, 2019
)
0.51
" Pain visual analog scale (VAS) at rest and at flexion, patient's global assessment (PGA), patient-controlled analgesia (PCA) consumption, hospital for special surgery (HSS), knee score, and adverse events were assessed."( Comparison of analgesic effect, knee joint function recovery, and safety profiles between pre-operative and post-operative administrations of meloxicam in knee osteoarthritis patients who underwent total knee arthroplasty.
Liu, L; Shao, Y; Wang, J; Wang, S; Yang, J; Zhai, Y; Zhao, X, 2020
)
0.56
" Regarding safety, the incidence of adverse events was of no difference between the two groups."( Comparison of analgesic effect, knee joint function recovery, and safety profiles between pre-operative and post-operative administrations of meloxicam in knee osteoarthritis patients who underwent total knee arthroplasty.
Liu, L; Shao, Y; Wang, J; Wang, S; Yang, J; Zhai, Y; Zhao, X, 2020
)
0.56
" This study evaluated the toxic effects caused by the treatment involving repeated low at higher doses of meloxicam in mice, by genotoxicity, oxidative stress, and histopathological parameters."( Repeated dose of meloxicam induces genotoxicity and histopathological changes in cardiac tissue of mice.
Betti, AH; Bigolin, C; da Silva, JCG; da Silva, LB; Dallegrave, E; Farias, DG; Gehlen, G; Kayser, JM; Moraes, MF; Neumann, TMSO; Perassolo, MS; Raasch, JR; Rodrigues, GZP; Schiling, G; Schuster, AC; Staudt, LBM, 2022
)
0.72
" In Phase III trials, it demonstrated adverse event profile similar to placebo, with nausea, constipation, vomiting and headache occurring most frequently."( Meloxicam for intravenous use: review of its clinical efficacy and safety for management of postoperative pain.
Berkowitz, RD; Mack, RJ; McCallum, SW, 2021
)
0.62
" Adverse events (AEs) were reported for 69."( Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.
Berkowitz, RD; Black, LK; Coyle, E; Du, W; Freyer, A; Mack, RJ; McCallum, SW; Sah, AP; Steinfeld, R, 2021
)
0.62
" These patients require an effective and safe analgesic alternative."( Meloxicam and/or Etoricoxib Could Be Administered Safely in Two Equal Doses during an Open Oral Challenge in Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.
Martínez, DM; Ramírez Zuluaga, LF; Rojas-Mejía, DV; Serrano Reyes, CD; Silva Espinosa, DL, 2021
)
0.62
"Open oral provocation with meloxicam and etoricoxib carried out in 2 steps without placebo seems to be safe and implies less costs and less time expenditure."( Meloxicam and/or Etoricoxib Could Be Administered Safely in Two Equal Doses during an Open Oral Challenge in Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.
Martínez, DM; Ramírez Zuluaga, LF; Rojas-Mejía, DV; Serrano Reyes, CD; Silva Espinosa, DL, 2021
)
0.62
" Moreover, the occurrence of adverse events was similar between the 2 groups."( Evaluation of analgesic effect, joint function recovery and safety of meloxicam in knee osteoarthritis patients who receive total knee arthroplasty: A randomized, controlled, double-blind study.
Hu, F; Wu, G; Wu, J; Zhao, Q, 2021
)
0.62
" These findings suggest that 20 mg/kg of meloxicam in mice causes gastric toxicity when given for 3 or 7 d and should be used cautiously; however, carprofen at 20 mg/kg appears to have minimal toxic effects with regard to the parameters measured."( Toxic Effects of High-dose Meloxicam and Carprofen on Female CD1 Mice.
Bailey, AL; Kendall, LV; McGee, W; Singh, B, 2022
)
0.72
" This study aimed to determine the tolerability and adverse event profile of combined toceranib and low dose meloxicam in cancer-bearing cats."( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman, SJ; Pellin, MA, 2022
)
0.72
"02 mg/kg q24h was safe and well tolerated, with no cats being withdrawn due to adverse events from the drug combination."( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman, SJ; Pellin, MA, 2022
)
0.72
"Low dose meloxicam combined with toceranib is safe and well tolerated in cancer-bearing cats."( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman, SJ; Pellin, MA, 2022
)
0.72
", celecoxib) are believed to have fewer gastrointestinal (GI) adverse effects than nonselective NSAIDS."( Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost.
Breckenridge, L; Fillingham, YA; Gursay, D; Haffar, A; Lonner, JH, 2022
)
0.72
" Cutaneous adverse effects caused by interaction between UVA radiation and exogenous factors can manifest as phototoxic reactions."( The Assessment of Meloxicam Phototoxicity in Human Normal Skin Cells: In Vitro Studies on Dermal Fibroblasts and Epidermal Melanocytes.
Banach, K; Karkoszka, M; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D, 2022
)
0.72
" Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic."( Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022
)
0.72
"Selective COX-2 inhibitor NSAIDs are safe in patients with N-ERD."( Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study.
Çakmak, ME, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" These pharmacodynamic findings correlated with the pharmacokinetic properties of miloxicam."( Pharmacodynamics and pharmacokinetics of miloxicam in the horse.
Busch, U; Higgins, AJ; Lees, P; Pugh, KE; Sedgwick, AD,
)
0.13
" The mean terminal phase elimination half-life was reduced from 19."( The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.
Busch, U; Heinzel, G; Narjes, H, 1995
)
0.29
" Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is > 99."( A review of the clinical pharmacokinetics of meloxicam.
Busch, U; Roth, W; Türck, D, 1996
)
0.29
" MRT and tmax were also unchanged, while the elimination rate constant was decreased slightly by 12%, which is of no therapeutic relevance."( The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin.
Degner, FL; Heinzel, G; Narjes, H; Türck, D, 1995
)
0.29
" Dose-proportionality was demonstrated with respect to Cmax (maximum plasma concentration) and AUC (extrapolated area under the plasma concentration-time curve from zero time to infinity) over a range of 5-30 mg."( Pharmacokinetics and tolerability of meloxicam after i.m. administration.
Busch, U; Heinzel, G; Narjes, H; Nehmiz, G; Türck, D, 1996
)
0.29
"The pharmacodynamic properties of meloxicam, a new nonsteroidal antiinflammatory drug (NSAID), that go beyond those typical of an NSAID were examined."( General pharmacology of meloxicam--Part II: Effects on blood pressure, blood flow, heart rate, ECG, respiratory minute volume and interactions with paracetamol, pirenzepine, chlorthalidone, phenprocoumon and tolbutamide.
Engelhardt, G; Homma, D; Schlegel, K; Schnitzler, C; Utzmann, R, 1996
)
0.29
" Pharmacokinetic parameters were determined after haemodialysis."( Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers.
Heinzel, G; Höffler, D; Narjes, HH; Nehmiz, G; Schwarz, A; Türck, D, 1996
)
0.29
" This was observed in association with raised free Cmax (5."( Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers.
Heinzel, G; Höffler, D; Narjes, HH; Nehmiz, G; Schwarz, A; Türck, D, 1996
)
0.29
"Meloxicam has displayed a pharmacokinetic profile in end-stage renal failure which is similar to that observed for other highly protein bound nonsteroidal anti-inflammatory drugs (NSAIDs)."( Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers.
Heinzel, G; Höffler, D; Narjes, HH; Nehmiz, G; Schwarz, A; Türck, D, 1996
)
0.29
" Meloxicam plasma concentrations were determined from blood samples taken during the study and pharmacokinetic parameters calculated according to noncompartmental methods."( Meloxicam pharmacokinetics in renal impairment.
Bevis, PJ; Boulton-Jones, JM; Geddes, CG; Heinzel, G; Nehmiz, G; Türck, D, 1997
)
0.3
"Subjects with no or mild renal impairment showed similar pharmacokinetic profiles (geometric mean AUCSS (%gCV) 55 (33%) vs 55 (38%) micrograms ml-1 h)."( Meloxicam pharmacokinetics in renal impairment.
Bevis, PJ; Boulton-Jones, JM; Geddes, CG; Heinzel, G; Nehmiz, G; Türck, D, 1997
)
0.3
"To investigate the pharmacokinetic interaction of oral meloxicam with intravenous (i."( Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis.
Degner, FL; Hübner, G; Rau, R; Sander, O; Türck, D, 1997
)
0.3
"The pharmacokinetic profile of the new nonsteroidal anti-inflammatory drug meloxicam was investigated in a number of animal species, including mice, rats, dogs, mini-pigs, and baboons, after administration of [14C]meloxicam."( Pharmacokinetics of meloxicam in animals and the relevance to humans.
Baierl, J; Busch, U; Heinzel, G; Huber, C; Roth, W; Schmaus, H; Schmid, J, 1998
)
0.3
" Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration."( Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug.
Davies, NM; Skjodt, NM, 1999
)
0.3
" Meloxicam is completely absorbed from the gastrointestinal tract and has an elimination half-life of 24 hours in the dog."( [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].
Hörstermann, D; Poulsen Nautrup, B, 1999
)
0.3
" The study was also extended to determine the pharmacokinetic profile of a newer formulation of meloxicam gel after topical application on depilated skin of rats."( Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application.
Bansal, P; Bhardwaj, RK; Gupta, SK; Jaiswal, J; Velpandian, T,
)
0.13
" Plasma concentrations of the drugs were determined by validated high-performance liquid chromatography methods and pharmacokinetic parameters were calculated."( Comparative pharmacokinetics of three non-steroidal anti-inflammatory drugs in five bird species.
Baert, K; De Backer, P, 2003
)
0.32
"To perform a nonlinear mixed effect modelling (NONMEM) population pharmacokinetic analysis of meloxicam plasma concentrations in rheumatoid arthritis (RA) patients participating in three clinical trials, and to evaluate the effects of age, weight, gender and concomitant medications on meloxicam pharmacokinetics."( Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.
Meineke, I; Türck, D, 2003
)
0.32
"The population pharmacokinetic meloxicam data from patients with RA gave similar results to those obtained from phase I trials."( Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.
Meineke, I; Türck, D, 2003
)
0.32
"To assess the pharmacokinetic profile of single doses of meloxicam in healthy Chinese volunteers."( [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
Xu, HY; Zhang, BJ; Zhang, YF; Zhao, LM; Zhong, DF, 2001
)
0.31
" The pharmacokinetic parameters were subjected to Shapiro-Wilk test to determine whether these data were fitted to a normal distribution."( [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
Xu, HY; Zhang, BJ; Zhang, YF; Zhao, LM; Zhong, DF, 2001
)
0.31
"The twenty volunteers can be classified into extensive metabolizers and poor metabolizers according to pharmacokinetic parameters."( [Pharmacokinetics of meloxicam in healthy Chinese volunteers].
Xu, HY; Zhang, BJ; Zhang, YF; Zhao, LM; Zhong, DF, 2001
)
0.31
" Pharmacokinetic parameters after the first dose were calculated by noncompartmental methods."( Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis.
Burgos-Vargas, R; Foeldvari, I; Linke, R; Thon, A; Tuerck, D, 2004
)
0.32
"To determine pharmacokinetic parameters for meloxicam, a nonsteroidal anti-inflammatory drug, in horses."( Pharmacokinetics of meloxicam in plasma and urine of horses.
Bonnaire, Y; Garcia, P; Hirsch, A; Laroute, V; Narbe, R; Popot, MA; Reymond, N; Toutain, PL, 2004
)
0.32
"5 mg) tablets and to obtain pharmacokinetic parameters of this molecule in Mexican population not reported previously."( Bioequivalence evaluation of two brands of meloxicam tablets (Promotion and Mobicox): pharmacokinetics in a healthy female Mexican population.
Angeles, AP; Contreras, L; Fernández, A; García, A; Hernández, JA; Hinojosa, M; Marcelín-Jiménez, G; Martínez-Rossier, L; Morales, M; Rivera, L, 2005
)
0.56
" Meloxicam has a plasma half-life of approximately 20 h and is convenient for once daily administration."( Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.
Davies, NM; Gates, BJ; Nguyen, TT; Setter, SM, 2005
)
0.33
"We evaluated the pharmacokinetic profile of meloxicam (0."( Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing.
Chen, HC; Taylor, WM; Turner, PV, 2006
)
0.33
"To determine the disposition of a bolus of meloxicam (administered IV) in horses and donkeys (Equus asinus) and compare the relative pharmacokinetic variables between the species."( Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys.
Bennett, BS; Matthews, NS; Mealey, KL; Peck, KE; Sinclair, MD; Taylor, TS, 2006
)
0.33
" The serum concentration-time curve for each horse and donkey was analyzed separately to estimate standard noncompartmental pharmacokinetic variables."( Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys.
Bennett, BS; Matthews, NS; Mealey, KL; Peck, KE; Sinclair, MD; Taylor, TS, 2006
)
0.33
" Also further pharmacokinetic parameters were well comparable."( Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects.
Erenmemişoğlu, A; Gschwend, MH; Hincal, AA; Kanzik, I; Martin, W; Tamur, U, 2007
)
0.34
" The AUCinf, Cmax, tmax and t1/2 were 42."( Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study.
Bae, JW; Jang, CG; Kim, MJ; Lee, SY, 2007
)
0.34
" However, the possible cumulative pharmacokinetic and pharmacodynamic effects in vultures receiving multiple daily doses of meloxicam over time were not assessed."( The pharmacokinetics of meloxicam in vultures.
Bartels, P; Bekker, L; Cromarty, AD; Cuthbert, R; McGaw, L; Naidoo, V; Swan, GE; Taggart, MA; Wolter, K, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"19 L/kg) and the elimination half-life was short (2."( Pharmacokinetics and pharmacodynamics of meloxicam in piglets.
Fosse, TK; Haga, HA; Haugejorden, G; Hormazabal, V; Horsberg, TE; Ranheim, B, 2008
)
0.35
" Serial (0-48h) blood samples were collected for pharmacokinetic and bioavailability studies."( Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi, A; Jamali, F, 2008
)
0.35
" While the communication provides relevant case studies to support the hypothesis in both dental pain and migraine attacks, it also provides biopharmaceutical and pharmacokinetic challenges of developing such a strategy for faster oral drug absorption."( Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.
Srinivas, NR,
)
0.13
"The potential for topical delivery of meloxicam was investigated by examining its pharmacokinetic profiles in plasma and synovial fluid following oral and transdermal administration in Beagle dogs."( Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs.
Chen, XY; Li, SM; Wei, XY; Yao, HM; Yuan, Y; Zhong, DF, 2009
)
0.35
"The pharmacokinetic results showed that AUC(0-t) (23."( Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs.
Chen, XY; Li, SM; Wei, XY; Yao, HM; Yuan, Y; Zhong, DF, 2009
)
0.35
" Pharmacokinetic analysis of the meloxicam was determined via noncompartmental analysis."( Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus).
Carpenter, JW; Hunter, RP; Koch, DE; Pollock, CG, 2009
)
0.35
" Plasma samples collected up to 96 hours after administration were analyzed by liquid chromatography/mass spectrometry followed by noncompartmental pharmacokinetic analysis."( Pharmacokinetics of intravenous and oral meloxicam in ruminant calves.
Allen, PS; Coetzee, JF; KuKanich, B; Mosher, R, 2009
)
0.35
"The objectives of these investigations were: first, to describe the pharmacokinetic properties of meloxicam in cats following single and multiple oral administration and secondly, to simulate different oral dosage regimes for meloxicam in cats after multiple dose administration to illustrate and evaluate those dosage regimes for the alleviation of inflammation and pain in cats."( Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats.
Jöns, O; Kloft, C; Lehr, T; Narbe, R; Staab, A, 2010
)
0.36
" Plasma drug concentrations were determined over 48h post-administration by liquid chromatography/mass spectrometry followed by non-compartmental pharmacokinetic analysis."( Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves.
Coetzee, JF; Cull, CA; Kelly, LL; Kohake, LE; KuKanich, B; Mosher, RA; Mueting, SL, 2011
)
0.37
"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12."( Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana).
Barron, GH; Budsberg, SC; Divers, SJ; Hernandez, SM; Koch, TF; McBride, M; Papich, M; Perpinan, D; Pethel, M; Stedman, NL, 2010
)
0.36
" In a randomized, cross-over design the pharmacokinetic parameters were investigated in adult goats (n = 8) after single intravenous and oral administration."( Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids.
Bondesson, U; Högberg, M; Ingvast-Larsson, C; Mengistu, U; Olsén, L; Olsson, K, 2011
)
0.37
" The pharmacodynamic effects of meloxicam were determined by measuring TXB(2) generated in blood."( Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.
Bae, JW; Choi, CI; Jang, CG; Lee, SY, 2011
)
0.37
"The CYP2C9*1/*13 genotype is associated with decreased metabolism and increased pharmacodynamic effects of meloxicam."( Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.
Bae, JW; Choi, CI; Jang, CG; Lee, SY, 2011
)
0.37
" In this contribution, we describe how a novel method can be used for coformer selection to enable the efficient and effective development of a pharmaceutical cocrystal with desired physicochemical and pharmacokinetic properties."( Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics.
Cheney, ML; Hanna, M; Shan, N; Weyna, DR; Wojtas, L; Zaworotko, MJ, 2011
)
0.37
" Pharmacodynamic data were modeled using an indirect response pharmacokinetic/pharmacodynamic model."( Paw inflammation model in dogs for preclinical pharmacokinetic/pharmacodynamic investigations of nonsteroidal anti-inflammatory drugs.
Bargues, IA; Giraudel, JM; Jeunesse, EC; Lacroix, MZ; Letellier, IM; Toutain, CE; Toutain, PL, 2011
)
0.37
" The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t(1/2β) ) was 40."( The pharmacokinetics and metabolism of meloxicam in camels after intravenous administration.
Agha, BA; Al Ali, WA; Al Biriki, NA; Al Neaimi, KM; Kamel, AM; Wasfi, IA, 2012
)
0.38
" The absorption half-life was relatively short (0."( Pharmacokinetics and pharmacodynamic effects of meloxicam in piglets subjected to a kaolin inflammation model.
Fosse, TK; Haga, HA; Horsberg, TE; Ranheim, B; Spadavecchia, C, 2011
)
0.37
" Plasma and milk drug concentrations were determined over 7 days postadministration by HPLC/MS followed by noncompartmental pharmacokinetic analyses."( Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows.
Coetzee, JF; Gehring, R; Kukanich, B; Malreddy, PR, 2013
)
0.39
" In addition, pharmacokinetic profiles over four hours were acquired after oral administration of a 10 mg/kg (meloxicam equivalent) solid suspension in rats."( Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.
Cheney, ML; Hanna, M; Sanchez-Ramos, JR; Sava, V; Shan, N; Song, S; Weyna, DR; Zaworotko, MJ, 2012
)
0.38
" Plasma samples collected up to 96 hours post-administration were analyzed by high pressure liquid chromatography and mass spectrometry detection (HPLC-MS) followed by non-compartmental pharmacokinetic analysis."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
"0 hours) with a half-life (T ½ λz) of 22."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
"9 ng/mL and elimination half-life 10."( Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.
Boston, R; Edwards, S; Lievaart, J; Noble, G; Pippia, J; Raidal, SL,
)
0.13
" Pharmacokinetic profiling of an orally administered MEL salt was also carried out in both normal rats and rats treated with propantheline for the suppression of gastric motility."( Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
Inoue, R; Ochi, M; Onoue, S; Yamada, S; Yamauchi, Y, 2013
)
0.39
"The pharmacokinetic profile of meloxicam in clinically healthy koalas (n = 15) was investigated."( Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration.
Black, LA; Gilchrist, S; Gillett, A; Govendir, M; Higgins, DP; Kimble, B; Krockenberger, MB; Li, KM; Valtchev, P, 2013
)
0.39
" In this study, we compared the pharmacokinetic parameters and effect of preemptive analgesics administered to calves subjected to dehorning with local anesthesia."( The pharmacokinetics and effects of meloxicam, gabapentin, and flunixin in postweaning dairy calves following dehorning with local anesthesia.
Allen, KA; Bergamasco, LL; Coetzee, JF; Dockweiler, JC; Edwards-Callaway, LN; Fraccaro, E; Glynn, HD; Jones, M; KuKanich, B; Lubbers, B, 2013
)
0.39
" Plasma meloxicam concentrations were determined, and noncompartmental pharmacokinetic analysis was performed."( Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses.
Carpenter, JW; Fredholm, DV; Kohles, M; KuKanich, B, 2013
)
0.39
" Computer software was used to estimate values of pharmacokinetic parameters through noncompartmental methods."( Pharmacokinetics of intravenously and orally administered meloxicam in sheep.
Coetzee, JF; KuKanich, B; Smith, BI; Stock, ML, 2013
)
0.39
"Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14."( Pharmacokinetics of intravenously and orally administered meloxicam in sheep.
Coetzee, JF; KuKanich, B; Smith, BI; Stock, ML, 2013
)
0.39
" In vitro half-life for disappearance of each compound was converted to hepatic clearance using the well stirred model, with and without correction for plasma protein binding."( Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac.
Chan, TS; Kehtani, SR; Khetani, SR; Moore, A; Tweedie, D; Yu, H, 2013
)
0.39
" Red-tailed hawks were determined to have the shortest elimination half-life for meloxicam (0."( Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Boothe, DM; Gamble, KC; Lacasse, C, 2013
)
0.39
" Plasma meloxicam concentrations were quantified with liquid chromatography-mass spectrometry, and noncompartmental pharmacokinetic analysis was performed."( Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days.
Carpenter, JW; Delk, KW; Kohles, M; KuKanich, B; Nietfeld, JC, 2014
)
0.4
" We determined the pharmacokinetic properties of a single subcutaneous dose of meloxicam (0."( Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration.
Chinnadurai, SK; Harms, CA; Messenger, KM; Papich, MG, 2014
)
0.4
"0) was used for curve fitting and calculations of pharmacokinetic parameters."( Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.
Di, X; Jiang, N; Xu, J; Xu, L; Xu, X; Yang, Y; Zhang, M; Zhao, G, 2014
)
0.4
" Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868."( Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study.
Liew, KB; Loh, GO; Peh, KK; Tan, YT, 2014
)
0.4
" Here we investigated the pharmacokinetic parameters of 3 formulations of meloxicam in cynomolgus macaques."( Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).
Bauer, C; Frost, P; Kirschner, S, 2014
)
0.4
" Plasma samples collected up to 48 h postadministration were analyzed by high-pressure liquid chromatography and mass spectrometry (HPLC-MS) followed by noncompartmental pharmacokinetic analysis."( Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration.
Coetzee, JF; Johnson, AK; Karriker, LA; KuKanich, B; Millman, ST; Pairis-Garcia, MD; Stalder, KJ; Wulf, L, 2015
)
0.42
" However, the elimination of meloxicam in cetaceans was slower than in other species, with an elimination half-life of almost 70 hr, and detectable drug concentrations up to 7 days."( Pharmacokinetics of single dose oral meloxicam in bottlenose dolphins (Tursiops truncatus).
Jensen, ED; Meegan, JM; Nollens, HH; Papich, MG; Schmitt, TL; Simeone, CA; Smith, CR, 2014
)
0.4
" We describe the pharmacokinetic behavior of meloxicam in the loggerhead sea turtle (Caretta caretta)."( Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration.
Cavaliere, L; Crescenzo, G; Di Bello, A; Freggi, D; Lai, OR; Marzano, G; Soloperto, S, 2015
)
0.42
" The geometric mean ratios (GMR test/reference) and the 90% confidence intervals of the pivotal pharmacokinetic parameters (area under the curve and maximum concentration) were within the defined limits of 80% to 125% generally accepted for products to be considered bioequivalent."( Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
Banse, H; Barker, J; Cribb, AE; Engbers, S; Fischer, C; Frederick, J; Friedt, H; Rybicka, JM; Stastny, T; Vivancos, M, 2015
)
0.42
" Concentration-time curves were fitted and pharmacokinetic parameters were estimated for each administration group."( Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration.
Bilgen, M; Boyacioglu, M; Erdogan, H; Karademir, U; Kum, C; Sekkin, S, 2016
)
0.43
" The terminal half-life was longer (15."( Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration.
Bilgen, M; Boyacioglu, M; Erdogan, H; Karademir, U; Kum, C; Sekkin, S, 2016
)
0.43
" This study investigated the pharmacokinetic (PK) properties of SoluMatrix meloxicam 5-mg (fasting conditions) and 10-mg capsules (fasting and fed conditions) and compared SoluMatrix meloxicam 10-mg capsules with meloxicam 15-mg tablets under fasting conditions."( Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults.
Hussaini, A; Solorio, D; Young, C, 2016
)
0.43
"Studies have shown altered pharmacokinetic patterns (PK) in patient suffering from acute pain."( Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions.
Aghazadeh-Habashi, A; Almukainzi, M; Jamali, F; Löbenberg, R, 2016
)
0.43
"To examine whether strict control of clinical trial conditions could reduce apparent differences of pharmacokinetic (PK) parameters among ethnic groups."( Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C, 2016
)
0.43
" Cmax values of moxifloxacin and simvastatin, but not meloxicam, showed significant differences."( Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C, 2016
)
0.43
" With the aim to fill the lack of data about its pharmacokinetic in this species, eighteen turtles (Trachemys scripta scripta) were divided in three groups and treated with a single dose of meloxicam (0."( Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations.
Catanzaro, A; Deli, G; della Rocca, G; Di Salvo, A; Giorgi, M, 2016
)
0.43
"To determine the pharmacokinetics of meloxicam in Caribbean flamingos ( Phoenicopterus ruber ruber), a pilot study was performed first, followed by a complete pharmacokinetic study."( Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber).
Carpenter, JW; KuKanich, B; Lindemann, DM, 2016
)
0.43
" Pharmacokinetic values for each administration route were determined with a 2-compartment open model approach."( Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections.
Aboubakr, M; Altan, F; Cetin, G; Dik, B; Uney, K, 2016
)
0.43
" Pharmacokinetic parameters were determined by data plotting followed by analysis with a noncompartmental model."( Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy.
Beaudry, F; Benito, J; Lascelles, BD; Lavoie, AM; Monteiro, BP; Steagall, PV, 2016
)
0.43
"Critically evaluating the pharmacokinetic behavior of a drug in the body provides crucial information about how to effectively treat a patient."( PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS).
Fredholm, DV; KuKanich, B; Mylniczenko, ND, 2016
)
0.43
" Pharmacokinetic values were determined from plasma concentrations measured by high-performance liquid chromatography."( Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor).
Papich, MG; Pich, AA; Sánchez, CR; Unger, KM; Zordan, MA, 2016
)
0.43
" Estimated values of selected pharmacokinetic parameters were compared by use of a linear mixed-effects ANOVA."( Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber).
Boonstra, JL; Cox, SK; Martin-Jimenez, T, 2017
)
0.46
"In this study, we evaluated the pharmacokinetic profiles of meloxicam and sustained-release (SR) buprenorphine in prairie dogs."( Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (
Cary, CD; Gallardo-Romero, NF; Hutson, CL; Lathrop, GW; Lukovsky-Akhsanov, NL; Morgan, CN; Ostergaard, SD; Powell, N; Tansey, CM; Taylor, WD, 2017
)
0.46
"This study evaluated the pharmacokinetic profile of a single dose of meloxicam (1."( Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (
Eshar, D; Kukanich, B; McCullough, C; Warner, M; Wright, TL, 2017
)
0.46
" Although commonly used in avian medicine, limited pharmacokinetic (PK) data in domestic and companion birds are available."( Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus).
Antonissen, G; Croubels, S; De Backer, P; De Baere, S; Devreese, M; Dhondt, L; Gehring, R; Goessens, T; Haesendonck, R, 2017
)
0.46
"The aims of the investigation were to establish for the first time (i) clinical efficacy and (ii) pharmacokinetic profile of meloxicam intravenously (IV) administered in male Mediterranean buffalo calves after surgical orchiectomy."( Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis).
Borriello, G; Cagnardi, P; Ciaramella, P; D'Andrea, L; Di Loria, A; Ferrante, MC; Guccione, J; Villa, R; Zicarelli, L, 2017
)
0.46
"  Meloxicam, a COX-2 selective nonsteroidal anti-inflammatory medication, has been used in many exotic animals at doses extrapolated from domestic animal pharmacokinetic and pharmacodynamic studies."( PHARMACOKINETICS OF MELOXICAM FOLLOWING A SINGLE ORAL DOSE IN MALAYAN FLYING FOXES ( PTEROPUS VAMPYRUS).
Cox, S; Goodnight, AL, 2018
)
0.48
" Analysis of meloxicam in plasma samples was conducted with the use of reversed-phase high-performance liquid chromatography, and pharmacokinetic parameters were calculated by noncompartmental analysis."( PHARMACOKINETICS OF A SUSTAINED-RELEASE FORMULATION OF MELOXICAM AFTER SUBCUTANEOUS ADMINISTRATION TO AMERICAN FLAMINGOS ( PHOENICOPTERUS RUBER).
Cox, SK; Sim, RR, 2018
)
0.48
" Blood samples were collected 12 and 24 hours after each drug administration (times of presumptive peak and trough drug concentrations) for pharmacokinetic analysis."( Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus).
Ardiaca, M; Bonvehí, C; Encinas, T; Gilabert, JA; Montesinos, A; Orós, J, 2019
)
0.51
"To characterize the pharmacokinetics of a novel granule meloxicam formulation in fasted and fed horses, and to compare pharmacokinetic features with oral suspension and tablets."( Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.
Mendoza, FJ; Perez-Ecija, A; Serrano-Rodriguez, JM, 2019
)
0.51
" Blood samples were collected for pharmacokinetic analysis, and vital signs, hematology, and biochemistry variables were monitored for 72 hours."( Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.
Mendoza, FJ; Perez-Ecija, A; Serrano-Rodriguez, JM, 2019
)
0.51
" Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively)."( Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.
Mendoza, FJ; Perez-Ecija, A; Serrano-Rodriguez, JM, 2019
)
0.51
"Plasma pharmacokinetic profiles and the anti-inflammatory efficacy of meloxicam were determined when administered subcutaneously (SC) or intramuscularly (IM) to sheep."( Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep.
Govendir, M; Kimble, B; Lomax, S; Van der Saag, D; White, PJ; Woodland, AN, 2019
)
0.51
"The purpose of this study was two-fold: I) to determine the pharmacokinetic profile of meloxicam (MLX) in geese after intravenous (IV) and oral (PO) administration and II) to assess tissue residues in muscle, heart, liver, lung, and kidney."( Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese.
Giorgi, M; Lisowski, A; Owen, H; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
" The plasma and milk drug concentrations were determined by high-performance liquid chromatography with diode array detector, and the pharmacokinetic analysis was carried out by noncompartmental analysis."( Impact of lactation on pharmacokinetics of meloxicam in goats.
Giorgi, M; Kim, TW; Lisowski, A; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
" The primary pharmacokinetic parameters were calculated using a noncompartmental model."( Pharmacokinetics of Meloxicam Tablets in Healthy Chinese Adults in the Fasting and Fed States: A Single-Site, Single-Dose, Randomized, Open, 2-Period, 2-Sequence, Crossover Bioequivalence Study.
Fang, L; Hao, R; Huang, H; Lin, S; Si, Y; Tong, S; Wang, Y; Wu, Y; Wu, Z; Ye, T; Yu, J; Zhao, D; Zhou, F; Zhu, J, 2022
)
0.72
" Plasma concentrations of meloxicam were measured with high-performance liquid chromatography-ultraviolet detection, and pharmacokinetic parameters were calculated by non-compartmental analysis."( Pharmacokinetics and bioavailability of meloxicam in rainbow trout (Oncorhynchus mykiss) broodstock following intravascular, intramuscular, and oral administrations.
Corum, O; Durna Corum, D; Terzi, E; Uney, K, 2022
)
0.72
"The pharmacokinetic values, median (range), were determined."( Wintertime pharmacokinetics of intravenously and orally administered meloxicam in semi-domesticated reindeer (Rangifer tarandus tarandus).
Hänninen, L; Laaksonen, S; Nurmi, H; Raekallio, M, 2022
)
0.72
" This study aimed to develop a physiologically based pharmacokinetic (PBPK) model for meloxicam in broiler chickens and laying hens to facilitate withdrawal interval (WDI) estimations."( A web-based interactive physiologically based pharmacokinetic (iPBPK) model for meloxicam in broiler chickens and laying hens.
Baynes, RE; Chou, WC; Davis, JL; Lin, Z; Richards, ED; Riviere, JE; Tell, LA; Yuan, L, 2022
)
0.72
" Noncompartmental analysis was used to calculate pharmacokinetic parameters."( Pharmacokinetics and Egg Residues of Oral Meloxicam in Bantam Cochin Chickens.
Bergman, J; Cox, S; Gerhardt, L; Harvill, L; Singleton, S; Souza, MJ; Stilz, CR, 2022
)
0.72
" The pharmacokinetic analysis was carried out using a non-compartmental approach."( Pharmacokinetics and effect on renal function and average daily gain in lambs after castration and tail docking, of firocoxib and meloxicam.
Dukkipati, V; Hunt, H; Kongara, K; Purchas, G; Speed, D; Venkatachalam, D; Ward, N, 2023
)
0.91
"There was no evidence for a difference in plasma elimination half-life between firocoxib given IM (LSM 18."( Pharmacokinetics and effect on renal function and average daily gain in lambs after castration and tail docking, of firocoxib and meloxicam.
Dukkipati, V; Hunt, H; Kongara, K; Purchas, G; Speed, D; Venkatachalam, D; Ward, N, 2023
)
0.91
"Both formulations of firocoxib had a long plasma elimination half-life and large volume of distribution."( Pharmacokinetics and effect on renal function and average daily gain in lambs after castration and tail docking, of firocoxib and meloxicam.
Dukkipati, V; Hunt, H; Kongara, K; Purchas, G; Speed, D; Venkatachalam, D; Ward, N, 2023
)
0.91
"Meloxicam showed long elimination half-life and high bioavailability following IM and oral administration."( Pharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration.
Corum, O; Coskun, D; Durna Corum, D; Uney, K, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this paper was to compare the effect of flumethasone and meloxicam in combination with oxytetracycline on clinical and immunological parameters of calves suffering from enzootic bronchopneumonia."( Effect of steroidal and non-steroidal anti-inflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia.
Bednarek, D; Kandefer-Szerszeń, M; Kondracki, M; Zdzisińska, B, 2003
)
0.32
"Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to interact with the oral anticoagulant warfarin and can cause a serious bleeding complication."( Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.
Ahn, H; Choi, KH; Kim, AJ; Kim, KB; Kim, KH; Lee, EB; Son, IJ, 2010
)
0.36
" This study determined the pharmacokinetics of oral (PO) gabapentin alone or in combination with meloxicam in ruminant calves."( Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves.
Coetzee, JF; Cull, CA; Kelly, LL; Kohake, LE; KuKanich, B; Mosher, RA; Mueting, SL, 2011
)
0.37
"Although meloxicam in combination with DC and weekly paclitaxel chemotherapy did not show promising therapeutic activity, it may provide some relief for neuropathy."( Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 trial.
Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H, 2011
)
0.37
"To compare the effects of tramadol alone, or in combination with dipyrone or meloxicam, on postoperative pain and analgesia requirement after unilateral mastectomy with or without ovariohysterectomy in dogs."( Effects of tramadol alone, in combination with meloxicam or dipyrone, on postoperative pain and the analgesic requirement in dogs undergoing unilateral mastectomy with or without ovariohysterectomy.
Bressan, TF; Campagnol, D; Coelho, K; Monteiro, BS; Monteiro, ER; Teixeira, RC, 2013
)
0.39
" Before the end of surgery, dogs were randomly assigned to receive intravenous tramadol alone (3 mg kg(-1), group T), combined with dipyrone (30 mg kg(-1), group TD) or meloxicam (0."( Effects of tramadol alone, in combination with meloxicam or dipyrone, on postoperative pain and the analgesic requirement in dogs undergoing unilateral mastectomy with or without ovariohysterectomy.
Bressan, TF; Campagnol, D; Coelho, K; Monteiro, BS; Monteiro, ER; Teixeira, RC, 2013
)
0.39
"Under the conditions of this study, tramadol alone or in combination with dypyrone or meloxicam provided effective analgesia for 24 hours in most dogs after unilateral mastectomy with or without ovariohysterectomy."( Effects of tramadol alone, in combination with meloxicam or dipyrone, on postoperative pain and the analgesic requirement in dogs undergoing unilateral mastectomy with or without ovariohysterectomy.
Bressan, TF; Campagnol, D; Coelho, K; Monteiro, BS; Monteiro, ER; Teixeira, RC, 2013
)
0.39
"This study examined the pharmacokinetics and analgesic effect of oral meloxicam (MEL) administered alone or in combination with gabapentin (GABA) in an experimental bovine lameness model."( Impact of oral meloxicam administered alone or in combination with gabapentin on experimentally induced lameness in beef calves.
Anderson, DE; Coetzee, JF; Gehring, R; Kohake, LE; Kukanich, B; Mosher, RA; Robert, B; Wang, C; White, BJ, 2014
)
0.4
" Herein we present a case of drug-drug interaction (meloxicam and desmopressin), in a patient also on clozapine, that ultimately resulted in hyponatremia and seizure."( Meloxicam-desmopressin drug-drug interaction producing hyponatremia.
Bojdani, E; Buonocore, S; Chen, A; Gurrera, R; Li, KJ, 2019
)
0.51
"In a patient with higher ADH levels, as in our patient taking desmopressin, the addition of an NSAID could further increase water retention and worsen hyponatremia; indeed, meloxicam was the only new medication added to the patient's regimen, and a drug interaction calculator supports the desmopressin-meloxicam drug-drug interaction as the culprit."( Meloxicam-desmopressin drug-drug interaction producing hyponatremia.
Bojdani, E; Buonocore, S; Chen, A; Gurrera, R; Li, KJ, 2019
)
0.51
"Infiltration of the surgical site with local anesthetics combined with nonsteroidal anti-inflammatory drugs may play an important role in improving perioperative pain control."( Comparison of perioperative analgesia using the infiltration of the surgical site with ropivacaine alone and in combination with meloxicam in cats undergoing ovariohysterectomy.
Bruno, TS; Cassu, RN; Costa Júnior, JS; de O L Carapeba, G; Giuffrida, R; Nicácio, GM; Nicácio, IPGA; Stelle, ABF; Teixeira Neto, FJ, 2020
)
0.56
"To compare extracorporeal shock wave therapy combined with oral medication and an exercise program vs sham treatment with medication and exercise for the treatment of chronic low back pain (CLBP)."( Extracorporeal Shock Wave Therapy Combined With Oral Medication and Exercise for Chronic Low Back Pain: A Randomized Controlled Trial.
Khosrawi, S; Ramezani, M; Taheri, P, 2021
)
0.62
"Extracorporeal shock wave therapy combined with oral medication and exercise was safe and effective in the short-term treatment of chronic low back pain."( Extracorporeal Shock Wave Therapy Combined With Oral Medication and Exercise for Chronic Low Back Pain: A Randomized Controlled Trial.
Khosrawi, S; Ramezani, M; Taheri, P, 2021
)
0.62
"Low dose meloxicam combined with toceranib is safe and well tolerated in cancer-bearing cats."( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats.
Keepman, SJ; Pellin, MA, 2022
)
0.72
"To observe the effect of warm acupuncture combined with meloxicam and comprehensive nursing on pain improvement and joint function in patients with knee osteoarthritis."( Effects of Warm Acupuncture Combined with Meloxicam and Comprehensive Nursing on Pain Improvement and Joint Function in Patients with Knee Osteoarthritis.
Li, X; Liu, F; Qu, X; Sun, Z; Wang, T, 2022
)
0.72
" The JG was treated with meloxicam combined with warm acupuncture."( Effects of Warm Acupuncture Combined with Meloxicam and Comprehensive Nursing on Pain Improvement and Joint Function in Patients with Knee Osteoarthritis.
Li, X; Liu, F; Qu, X; Sun, Z; Wang, T, 2022
)
0.72
"Warm acupuncture combined with meloxicam and comprehensive nursing can effectively improve knee swelling and pain in patients with KOA, and the mechanism may be related to reducing the content of inflammatory mediators."( Effects of Warm Acupuncture Combined with Meloxicam and Comprehensive Nursing on Pain Improvement and Joint Function in Patients with Knee Osteoarthritis.
Li, X; Liu, F; Qu, X; Sun, Z; Wang, T, 2022
)
0.72
" This open-label study (NCT03974932) evaluated the efficacy and safety of HTX-011 combined with an MMA regimen in patients undergoing TKA under spinal anesthesia."( HTX-011 in Combination with Multimodal Analgesic Regimen Minimized Severe Pain and Opioid Use after Total Knee Arthroplasty in an Open-Label Study.
Berkowitz, R; Hacker, S; Hu, J; Lee, GC; Rechter, A, 2023
)
0.91
"The aim of this study was to compare the effects of constant rate infusions (CRI) of fentanyl alone or combined with lidocaine and ketamine (FLK), on physiological parameters, isoflurane requirements and the number of postoperative analgesic rescues in dogs undergoing unilateral mastectomy."( Influence of Constant Rate Infusions of Fentanyl Alone or in Combination With Lidocaine and Ketamine on the Response to Surgery and Postoperative Pain in Isoflurane Anesthetized Dogs Undergoing Unilateral Mastectomy: A Randomized Clinical Trial.
Alievi, MM; de Oliveira, TF; Herrera-Becerra, JR; Marques, ÉJ; Monteiro, ER; Rovaris, IB; Tomazeli, D; Valle, SF,
)
0.13

Bioavailability

The objectives of this study were to prepare a powdered self-emulsified (SEDDS) formulation of meloxicam and to compare its oral bioavailability against commercial Mobic tablets.

ExcerptReferenceRelevance
" administration meloxicam was rapidly and completely absorbed (mean absolute bioavailability 102%)."( Pharmacokinetics and tolerability of meloxicam after i.m. administration.
Busch, U; Heinzel, G; Narjes, H; Nehmiz, G; Türck, D, 1996
)
0.29
" This open, randomized, crossover study was conducted to examine the effects of aspirin, the antacid Maalox (Rhone-Poulenc Rorer, Cologne, Germany), and cimetidine on the pharmacokinetics and bioavailability of a single oral dose of meloxicam 30 mg in healthy male volunteers."( Interaction of meloxicam with cimetidine, Maalox, or aspirin.
Busch, U; Heinzel, G; Narjes, H; Nehmiz, G, 1996
)
0.29
"This paper reviews recent studies that have aimed to establish the relative bioavailability of a new oral formulation of meloxicam, and to evaluate its safety and efficacy in a clinical setting."( Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations.
Hanft, G; Scheuerer, S; Sigmund, R; Türck, D, 2001
)
0.31
" After oral administration, bioavailability was nearly total regardless of feeding status (98 +/- 12% in fed horses and 85 +/- 19% in nonfed horses)."( Pharmacokinetics of meloxicam in plasma and urine of horses.
Bonnaire, Y; Garcia, P; Hirsch, A; Laroute, V; Narbe, R; Popot, MA; Reymond, N; Toutain, PL, 2004
)
0.32
" The effect of beta-CD on the bioavailability of meloxicam was also investigated in human volunteers using a balanced 2-way crossover study."( Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
Abdel-Salam, HM; El-Sayad, MA; Ghorab, MM; Mekhel, MM, 2004
)
0.32
"We conducted a randomized, crossover study in 23 healthy young female volunteers to compare the bioavailability of two brands of meloxicam (7."( Bioequivalence evaluation of two brands of meloxicam tablets (Promotion and Mobicox): pharmacokinetics in a healthy female Mexican population.
Angeles, AP; Contreras, L; Fernández, A; García, A; Hernández, JA; Hinojosa, M; Marcelín-Jiménez, G; Martínez-Rossier, L; Morales, M; Rivera, L, 2005
)
0.56
" These results suggested that meloxicam could be delivered to the colon with 15% (w/w) coating level of Eudragit FS 30 D and this polymer coating had no significant influence on the relative bioavailability of meloxicam of the pellets."( In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets.
Gao, C; Huang, J; Jiao, Y; Li, Y; Liu, Y; Mei, X; Shan, L, 2006
)
0.33
" It is practically insoluble in water leading to poor dissolution, variations in bioavailability and gastric irritation on oral administration."( Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk.
Mishra, DN; Vijaya Kumar, SG, 2006
)
0.33
"In this study, the bioavailability of 2 meloxicam 15 mg tablet formulations was compared."( Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies.
Borges, NC; Mendes, GD; Moreno, RA; Rigato, HM, 2006
)
0.33
" The bioavailability (%) of the optimal meloxicam sodium gel was about 50."( Formulation optimization of meloxicam sodium gel using response surface methodology.
Chang, JS; Hou, SS; Huang, YB; Tsai, YH; Wang, RJ; Wu, PC, 2007
)
0.34
"Application of a solid dispersion system is one of the methods used to increase the bioavailability of poorly water-soluble drugs."( Preparation of a solid dispersion by a dropping method to improve the rate of dissolution of meloxicam.
Bashiri-Shahroodi, A; Nassab, PR; Rajkó, R; Szabó-Révész, P, 2008
)
0.35
" We studied the pharmacokinetics of meloxicam and the effect of vagal suppression on the oral bioavailability and bioequivalence using a marketed (Brand) and a fast dissolving (FD) formulation."( Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi, A; Jamali, F, 2008
)
0.35
"To compare the bioavailability of two meloxicam tablet formulations (MEL-OD, Zydus Cadila Healthcare Limited, India, as a test formulation and Mobic, Boehringer Ingelheim International GmbH, Germany, as a reference formulation) in healthy Thai male volunteers under fasting condition."( Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers.
Gaysonsiri, D; Kampan, J; Kanjanawart, S; Phunikhom, K; Puapairoj, P; Simasathiansophon, S; Tangsucharit, P; Tassaneeyakul, W; Tiamkao, S; Vannaprasaht, S, 2009
)
0.55
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The purpose of this study was to investigate the pharmacokinetics and oral bioavailability of meloxicam in ruminant calves."( Pharmacokinetics of intravenous and oral meloxicam in ruminant calves.
Allen, PS; Coetzee, JF; KuKanich, B; Mosher, R, 2009
)
0.35
" The rate of absorption of MLX from ODT was significantly faster (p = 0."( A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design.
Aboelwafa, AA; Fahmy, RH,
)
0.13
" This may be due to an icreased systemic bioavailability of meloxicam after oral administration of its complex with beta-cyclodextrin."( Influence on analgesic activity and serum levels after meloxicam complexation with beta-cyclodextrin in mice and rats.
Dolezal, T; Janovský, M; Krsiak, M; Procháizková, M; Slíva, J, 2010
)
0.36
" After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11."( Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids.
Bondesson, U; Högberg, M; Ingvast-Larsson, C; Mengistu, U; Olsén, L; Olsson, K, 2011
)
0.37
" The oral bioavailability of ML-βCD-PEG was investigated by administration to rat and compared with ML and ML-βCD."( Preparation of meloxicam-β-cyclodextrin-polyethylene glycol 6000 ternary system: characterization, in vitro and in vivo bioavailability.
Moulay-Hassane, G; Radia, O; Rogalska, E,
)
0.13
"The practical applicability of solid dispersions (SD) for improvement of oral bioavailability of poorly water-soluble drugs has still remained limited because of lack of feasibility for scale-up of manufacturing processes."( An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.
Bandarkar, FS; Vavia, PR, 2011
)
0.37
" Meloxicam is practically insoluble in water (8µg/ml), which directly influences the C(max), T(max), as well as the bioavailability of the drug."( Development of meloxicam formulations utilizing ternary complexation for solubility enhancement.
Awasthi, SS; Kumar, SS; Kumar, TG; Manisha, P; Preeti, Y, 2011
)
0.37
"Stabilization of amorphous state is a focal area for formulators to reap benefits related with solubility and consequently bioavailability of poorly soluble drugs."( Moringa coagulant as a stabilizer for amorphous solids: Part I.
Bhende, S; Jadhav, N, 2012
)
0.38
" The oral bioavailability (F) of meloxicam (dose normalized) was 76% (Range: 48 - 92%)."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
"The mean bioavailability (F) of oral meloxicam was 76% indicating a high degree of gastrointestinal absorption."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
"The objectives of this study were to prepare a powdered self-emulsified (SEDDS) formulation of meloxicam and to compare its oral bioavailability against commercial Mobic tablets."( Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal, V; Alayoubi, A; Nazzal, S; Siddiqui, A, 2013
)
0.59
"To compare the bioavailability of a 15 mg meloxicam orodispersible tablet (ODT) and a reference 15 mg tablet in healthy volunteers."( Bioequivalence study of a novel orodispersible tablet of meloxicam in a porous matrix after single-dose administration in healthy volunteers.
Connolly, S; Granata, G; Leuratti, C; Loprete, L; Radicioni, M; Stroppolo, F, 2013
)
0.39
" Oral bioavailability was negligible in koalas."( Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration.
Black, LA; Gilchrist, S; Gillett, A; Govendir, M; Higgins, DP; Kimble, B; Krockenberger, MB; Li, KM; Valtchev, P, 2013
)
0.39
" Absolute systemic bioavailability of meloxicam after IM administration was 100% but was lower after oral administration (range, 49% to 75%)."( Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis).
Cole, GA; Court, MH; Gagnon, DJ; Hazarika, S; Molter, CM; Paul-Murphy, JR, 2013
)
0.39
" This study was conducted to evaluate the effect of formulation on the pharmacokinetics (PK) and comparative bioavailability of suspension (reference) and tablet (test) formulations of meloxicam."( Effect of the formulation on the bioequivalence of meloxicam: tablet and suspension.
El Bedaiwy, HM; Helmy, SA, 2013
)
0.39
"0 mg/kg has good bioavailability with slow elimination kinetics in sheep."( Pharmacokinetics of intravenously and orally administered meloxicam in sheep.
Coetzee, JF; KuKanich, B; Smith, BI; Stock, ML, 2013
)
0.39
"0-fold increase in bioavailability compared with unpulverized MEL."( Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors.
Hashimoto, I; Hashimoto, N; Kawachi, T; Ochi, M; Onoue, S; Toita, E; Yuminoki, K, 2014
)
0.4
"Postcataract endophthalmitis treatment through eye drops is of low corneal bioavailability and short residence time."( Bovine serum albumin-meloxicam nanoaggregates laden contact lenses for ophthalmic drug delivery in treatment of postcataract endophthalmitis.
Chen, J; Li, S; Liu, Y; Pan, W; Peng, J; Zhang, H; Zhang, W; Zu, D, 2014
)
0.4
" The main objective of the present work was to enhance the dissolution of MLX and thus its bioavailability by the aid of additives."( Utilization of spray drying technique for improvement of dissolution and anti-inflammatory effect of Meloxicam.
Alomrani, A; Badran, M; Shazly, G; Zoheir, K, 2015
)
0.42
" Furthermore, the area under the curve, and therefore systemic bioavailability (F = 31."( Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration.
Cavaliere, L; Crescenzo, G; Di Bello, A; Freggi, D; Lai, OR; Marzano, G; Soloperto, S, 2015
)
0.42
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
"05), but bioavailability was similar (98."( Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration.
Bilgen, M; Boyacioglu, M; Erdogan, H; Karademir, U; Kum, C; Sekkin, S, 2016
)
0.43
" The oral bioavailability was compared between these formulations in vagally suppressed rats (gastric dysfunction) and a control group."( Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions.
Aghazadeh-Habashi, A; Almukainzi, M; Jamali, F; Löbenberg, R, 2016
)
0.43
"4-fold increase in bioavailability compared with crystalline MEL."( Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability.
Hashimoto, N; Kanda, A; Kawachi, T; Kimura, K; Matsuda, A; Ochi, M; Yuminoki, K, 2016
)
0.43
" CONCLUSIONS AND CLINICAL RELEVANCE In lesser flamingos, oral administration of meloxicam resulted in higher bioavailability and a longer elimination half-life than did IM administration, but the maximum plasma concentration was low and may be insufficient to provide analgesia in flamingos."( Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor).
Papich, MG; Pich, AA; Sánchez, CR; Unger, KM; Zordan, MA, 2016
)
0.43
" In this study, PK parameters and absolute oral bioavailability expressed as percentage (F%) of celecoxib (10 mg/kg BW), mavacoxib (4 mg/kg BW) and meloxicam (1 mg/kg BW) were determined following single oral (PO) and intravenous (IV) administration to cockatiels (Nymphicus hollandicus)."( Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus).
Antonissen, G; Croubels, S; De Backer, P; De Baere, S; Devreese, M; Dhondt, L; Gehring, R; Goessens, T; Haesendonck, R, 2017
)
0.46
"The aim of the study was to assess the impact of the differences in dissolution profiles of meloxicam tablets on the in-vivo bioavailability parameters after oral administration."( Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Dong, W; He, Z; Jin, C; Liu, H; Shen, D; Zhao, C, 2018
)
0.48
"18%), no obvious skin irritation, decent relative bioavailability (122."( Fabrication of Tip-Dissolving Microneedles for Transdermal Drug Delivery of Meloxicam.
Chen, J; Huang, M; Huang, W; Huang, Z; Li, Q; Liu, S; Ye, Y, 2018
)
0.48
" These data suggest higher bioavailability as the underlying mechanism."( Comparison of milk and plasma pharmacokinetics of meloxicam in postpartum versus mid-lactation Holstein cows.
Burchard, M; Coetzee, JF; Gehring, R; Gorden, PJ; Kleinhenz, MD; Mochel, JP; Rajewski, SJ; Wang, C; Wulf, LW; Ydstie, JA, 2018
)
0.48
" Although dissolution profiles similar to the original product were obtained, the unexpected results of omeprazole low bioavailability in the fed bioequivalence study (BES I) showed the necessity to investigate the formulation in greater depth."( The effect of the composition of a fixed dose combination on bioequivalence results.
Beránek, J; Červená, T; Dumicic, A; Franc, A; Hofmann, J; Kukačková, L; Repický, A; Šalandová, J; Srbek, J; Vetchý, D; Vladovičová, B, 2018
)
0.48
"The prepared MX-BSA-NS significantly increased the inflammation-targeting properties and bioavailability of MX, suggesting its potential as a promising formulation for the targeted drug delivery of MX in future clinical applications."( A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects.
Chen, F; Gai, X; Li, Q; Liu, Y; Pan, W; Yang, X; Ye, M; Yu, S, 2018
)
0.48
" Bioavailability was high for every oral formulation, ranging 70%-110%, without feed effect."( Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.
Mendoza, FJ; Perez-Ecija, A; Serrano-Rodriguez, JM, 2019
)
0.51
"To investigate the pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs."( Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus).
Croubels, S; De Baere, S; Devreese, M; Hermans, K; Moeremans, I, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The average absolute PO bioavailability was 64."( Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese.
Giorgi, M; Lisowski, A; Owen, H; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
" The IM bioavailability of meloxicam was relatively lower in lactating (75."( Impact of lactation on pharmacokinetics of meloxicam in goats.
Giorgi, M; Kim, TW; Lisowski, A; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
"The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products."( Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia.
Ambrus, R; Bartos, C; Ducza, E; Gáspár, R; Ivanov, A; Janáky, T; Katona, G; Márki, Á; Sovány, T; Szabó-Révész, P; Tömösi, F, 2019
)
0.51
" The fluidMel and lyoMel samples had nearly five-fold higher relative bioavailability than nanoMel application by oral administration."( Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia.
Ambrus, R; Bartos, C; Ducza, E; Gáspár, R; Ivanov, A; Janáky, T; Katona, G; Márki, Á; Sovány, T; Szabó-Révész, P; Tömösi, F, 2019
)
0.51
"The solidification of the nanosuspension not only increased the stability of the Mel nanoparticles but also allowed the preparation of surfactant-free compositions with excellent bioavailability which may be an important consideration for certain groups of patients to achieve rapid analgesia."( Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia.
Ambrus, R; Bartos, C; Ducza, E; Gáspár, R; Ivanov, A; Janáky, T; Katona, G; Márki, Á; Sovány, T; Szabó-Révész, P; Tömösi, F, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56
" This common issue needs to be addressed, for this purpose a series of polyethylene glycol (PEG-4000) based nanogels were developed by free radical polymerization technique to enhance the solubility, dissolution, and bioavailability of poorly soluble drug meloxicam (MLX), as improved solubility is the significant application of nanosystems."( Synthesis of PEG-4000-co-poly (AMPS) nanogels by cross-linking polymerization as highly responsive networks for enhancement in meloxicam solubility.
Abdullah, O; Badshah, SF; Khan, KU; Khan, S; Minhas, MU; Munir, A; Sohail, M; Suhail, M, 2021
)
0.62
" ABCG2 is an efflux protein involved in the bioavailability and milk secretion of drugs."( Role of eprinomectin as inhibitor of the ruminant ABCG2 transporter: Effects on plasma distribution of danofloxacin and meloxicam in sheep.
Alvarez, AI; Alvarez-Fernandez, I; Blanco-Paniagua, E; Garcia-Lino, AM; Garcia-Mateos, D; Medina, JM; Merino, G, 2021
)
0.62
" Unfortunately, following the conventional application routes, the low brain bioavailability of MEL forms a significant limitation."( A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation.
Akel, H; Ambrus, R; Csóka, I; Ismail, R; Katona, G; Sabir, F, 2021
)
0.62
"The pharmacokinetics and bioavailability of meloxicam were investigated after single intravascular (IV), intramuscular (IM), and oral dose of 1 mg/kg in rainbow trout broodstock at 11 ± 1."( Pharmacokinetics and bioavailability of meloxicam in rainbow trout (Oncorhynchus mykiss) broodstock following intravascular, intramuscular, and oral administrations.
Corum, O; Durna Corum, D; Terzi, E; Uney, K, 2022
)
0.72
" Nanoemulsions represent a versatile formulation approach suitable for nasal drug delivery by increasing the absorption and the bioavailability of many drugs for systemic and nose-to-brain delivery due to their stability, small droplet size and optimal solubilization properties."( Mucoadhesive meloxicam-loaded nanoemulsions: Development, characterization and nasal applicability studies.
Budai-Szűcs, M; Csóka, I; Katona, G; Schelcz, Z; Sipos, B; Szabó-Révész, P; Szivacski, N; Volk, B; Zupkó, I, 2022
)
0.72
" Application of nano-sized active ingredients results in higher bioavailability because of their large specific surface area."( Development of extra-fine particles containing nanosized meloxicam for deep pulmonary delivery: In vitro aerodynamic and cell line measurements.
Ambrus, R; Burián, K; Hopp, B; Kókai, D; Nagy, A; Party, P, 2022
)
0.72
"Relative bioavailability of meloxicam and flunixin meglumine were reduced when compounded with ID in the same bottle and administered to piglets."( Pharmacokinetics of combined administration of iron dextran with meloxicam or flunixin meglumine in piglets.
Enouri, SS; Friendship, RM; Gu, Y; Johnson, RJ; O'Sullivan, TL; Ramkissoon, S, 2022
)
0.72
" In vivo release study of TZ and MX was performed in rabbits and results indicated the better pharmacokinetics parameters and improved the oral bioavailability when compared to the oral aqueous suspension and solution of TZ and MX, respectively."( Appraisal of the pharmacokinetic profile, histopathology and stability studies of a fast dissolving oral film based on natural polysaccharide.
Aamir, MN; Ajmal Shah, M; Alqarni, M; Blundell, R; Farid-Ul-Haq, M; Haseeb, MT; Sheikh, FA; Vargas-De-La-Cruz, C, 2022
)
0.72
" Therefore, growing interest has been witnessed in different particle size reduction techniques to improve the dissolution rates, transport characteristics and bioavailability of drugs."( A comprehensive analysis of meloxicam particles produced by nanosecond laser ablation as a wet milling technique.
Alapi, T; Ambrus, R; Burián, K; Homik, Z; Hopp, B; Kokai, D; Kopniczky, J; Náfrádi, M; Nagy, E; Smausz, T; Szabó-Révész, P, 2022
)
0.72
" The goal of the current study was to prepare and characterize chitosan encapsulated meloxicam nanoparticles (CEMNPs) with high bioavailability and less gastro intestinal toxicity in order to prevent such issues."( Chitosan Encapsulated Meloxicam Nanoparticles for Sustained Drug Delivery Applications: Preparation, Characterization, and Pharmacokinetics in Wistar Rats.
Halemani, GM; Hanumanthu, PB; Mannem, S; Nadoor, P; Prasad, TNVKV; Rajashekaraiah, R; Ramachandrappa, SC; Rao, S; Ubaradka, S; Yegireddy, M, 2022
)
0.72
"Meloxicam (MLX) is one of the most effective NSAIDs, but its poor water solubility and low bioavailability limit its clinical application."( Preparation and In Vitro and In Vivo Evaluation of Rectal In Situ Gel of Meloxicam Hydroxypropyl-β-cyclodextrin Inclusion Complex.
Lei, X; Li, D; Liu, Q; Peng, Y; Wang, C; Wang, T; Wu, Y; Yang, T; Zhang, G, 2023
)
0.91
"Meloxicam showed long elimination half-life and high bioavailability following IM and oral administration."( Pharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration.
Corum, O; Coskun, D; Durna Corum, D; Uney, K, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" This effect of meloxicam on furosemide dynamics is small, and is probably not clinically relevant in healthy volunteers under the dosing regime studied."( Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.
de Vaal, AC; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Schall, R, 1995
)
0.29
" The rectal temperature and scores for general demeanour were determined at 30-min intervals from before dosing to 300 min after the endotoxin challenge."( Dose-response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats.
Justus, C; Quirke, JF, 1995
)
0.29
" Neither hepatic insufficiency nor moderate renal dysfunction have any relevant effects on the pharmacokinetics of meloxicam and dosage adjustments in the elderly are not required."( A review of the clinical pharmacokinetics of meloxicam.
Busch, U; Roth, W; Türck, D, 1996
)
0.29
") diclofenac followed by oral dosing in patients with acute lumbago."( The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group.
Colberg, K; Degner, FL; Hettich, M; Sigmund, R, 1996
)
0.29
"On the basis of these results there is no necessity for a dosage adjustment when administering meloxicam to patients with mild to moderate renal impairment."( Meloxicam pharmacokinetics in renal impairment.
Bevis, PJ; Boulton-Jones, JM; Geddes, CG; Heinzel, G; Nehmiz, G; Türck, D, 1997
)
0.3
"5-30 mg) have been investigated in 78 healthy male volunteers after single and multiple dosing via oral, intravenous and rectal routes."( Clinical pharmacokinetics of meloxicam.
Busch, U; Heinzel, G; Narjes, H; Türck, D, 1997
)
0.3
"A blinded, randomized, controlled single crossover design study was performed to determine the efficacy of meloxicam, using 2 dosage groups."( Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs.
Budsberg, SC; Cross, AR; Keefe, TJ, 1997
)
0.3
" Similarly, a dose-response curve was obtained for Mel, 4'-Mel and piroxicam when measuring in vivo prostaglandin production, anti-inflammatory activity and gastric tolerance to determine the dose resulting in a 50% reduction of the each parameter."( Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.
Engelhardt, G; Mauz, A; Pairet, M; Schierok, H; Trummlitz, G; van Ryn, J, 1998
)
0.3
" Dosage adjustment is not required in the elderly."( Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug.
Davies, NM; Skjodt, NM, 1999
)
0.3
" The results confirm the recommended dosage regime of meloxicam with its initial loading dose and the subsequent maintenance dose."( [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].
Hörstermann, D; Poulsen Nautrup, B, 1999
)
0.3
" Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and prostaglandin E2 was measured in plasma as an index of monocyte COX-2 activity."( Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Di Giamberardino, M; Panara, MR; Patrignani, P; Patrono, C; Renda, G; Rotondo, MT; Santini, G; Sciulli, MG; Seta, F; Tacconelli, S, 1999
)
0.3
"To study the influence of meloxicam, a cyclooxygenase-2 (COX-2) preferential nonsteroidal anti-inflammatory drug, on serum thromboxane and platelet function in healthy volunteers with use of the maximum recommended daily dosage of 15 mg/day."( Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.
de Meijer, A; de Metz, M; Novakova, I; Thomas, C; Verbruggen, B; Vollaard, H, 1999
)
0.3
" As a result, drugs that have little or no COX-1 activity across their therapeutic dosage range have been developed."( COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
Hawkey, CJ; Jackson, LM, 2000
)
0.31
" The COX selectivity of each drug was evaluated from dose-response curves by calculating a ratio (COX-1:COX-2) of inhibitory concentration values on the basis of concentrations that reduced PGE2 by 50% in each COX model."( In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Benn, SJ; Conlon, P; Kay-Mugford, P; LaMarre, J, 2000
)
0.31
"The incidence of all adverse events was lower at each dosage of meloxicam than for diclofenac but greater than for placebo."( Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000
)
0.31
"Four simple and accurate methods are presented for the determination of meloxicam in dosage forms."( Spectrophotometric and fluorimetric methods for the determination of meloxicam in dosage forms.
Hassan, EM, 2002
)
0.31
" The method was successfully applied for the analysis of meloxicam in the tablet dosage form."( Electrochemical reduction of meloxicam at mercury electrode and its determination in tablets.
Beltagi, AM; Ghoneim, MM; Radi, A, 2002
)
0.31
" The method was validated and applied to the determination of meloxicam in tablets, which were in two different dosage forms."( Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma.
Altinöz, S; Kir, S; Nemutlu, E, 2002
)
0.31
" Choice of drug and of dosage is usually empirical, since studies of anti-inflammatory drugs are lacking."( Comparative pharmacokinetics of three non-steroidal anti-inflammatory drugs in five bird species.
Baert, K; De Backer, P, 2003
)
0.32
" The method was applied to the determination of six pharmaceutical preparations including two dosage forms."( Method development and validation for the analysis of meloxicam in tablets by CZE.
Kir, S; Nemutlu, E, 2003
)
0.32
"To evaluate the efficacy and safety of combined use of methotrexate and meloxicam for treating of ankylosing spondylitis (AS), and to determine the optimal dosage of methotrexate."( [Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety].
Kang, XT; Li, XH; Xie, RL, 2003
)
0.32
" The developed methods were successfully applied to the determination of LOX, TEX, and MEX in bulk powder, laboratory-prepared mixtures containing different percentages of degradation products, and pharmaceutical dosage forms."( Stability-indicating chromatographic methods for the determination of some oxicams.
Abdel Fattah, Lel-S; Salama, NN; Taha, EA,
)
0.13
"To determine pharmacokinetic-pharmacodynamic (PK-PD) relationships and dose effects for meloxicam in horses and to propose a suitable dosage for use in clinical studies."( Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint.
Cester, CC; Toutain, PL, 2004
)
0.32
" The second phase used a multiple-dose regimen (daily oral administration of meloxicam for 14 days), with meloxicam administered at the recommended dosage (0."( Pharmacokinetics of meloxicam in plasma and urine of horses.
Bonnaire, Y; Garcia, P; Hirsch, A; Laroute, V; Narbe, R; Popot, MA; Reymond, N; Toutain, PL, 2004
)
0.32
"The purpose of the study was to examine the clinical features of the course of coronary heart disease (CHD) in patients with rheumatoid arthritis (RA) and to evaluate the effects of the selective cyclooxygenase-2 (COG-2) inhibitor movalis (meloxicam) in two dosage forms (as injections and tablets) on the course of CHD in this group of patients."( [Use of meloxicam (movalis) in patients with rheumatic diseases with concomitant coronary heart disease].
Beliaeva, IB; Iakusheva, VA; Mazurov, VI, 2004
)
0.32
" It is possible, however, that local or topical treatment or altered dosing regimens may offer alternative approaches to the use of these drugs as antineoplastic agents."( The in vitro effects of piroxicam and meloxicam on canine cell lines.
Argyle, DJ; Chambers, G; Gault, E; Knottenbelt, C, 2006
)
0.33
" The proposed method is rapid, accurate and selective; it may be used for the quantitative analysis of meloxicam from raw materials, in bulk drugs and other dosage formulations."( A new RP-HPLC method for analysis of meloxicam in tablets.
Arayne, MS; Siddiqui, FA; Sultana, N, 2005
)
0.33
"5 mg/kg) given as single and repeated (once daily for 5 d) oral doses to female rabbits (n = 5/group) to define the optimal dose and dosing interval for clinical use."( Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing.
Chen, HC; Taylor, WM; Turner, PV, 2006
)
0.33
" The suggested procedures could be used for the determination of the above mentioned drugs in pure and dosage forms as well as in the presence of their degradation products."( Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl).
Fattah, Lel-S; Salama, NN; Taha, EA, 2006
)
0.33
" The following medications were randomly given to the patients who declared pain in the sixth hour after the operation: naproxen sodium, meloxicam, rofecoxib, paracetamol, dipyrone, and etodolac in proper dosage to form groups of 20 for each medication."( [Postoperative pain management in clinics of otolaryngology].
Cağici, CA; Calişkan, EE; Erkan, AN; Gencay, S; Ozlüoğlu, LN; Sener, M; Yavuz, H; Yilmaz, I; Yilmazer, C, 2006
)
0.33
"The results of this study confirm a high percentage of tolerability to the maximum therapeutic dosage of nabumetone and meloxicam in patients with NSAID intolerance, both in those with cutaneous/mucous manifestations and in those with respiratory disease."( Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
De Barrio, M; de Castro, FJ; Fernández-Bohórquez, M; Herrero, T; Martín, E; Prieto, A; Rubio, M; Ruiz, FJ; Tornero, P, 2007
)
0.34
"5 mg/kg) (MP group); and a group given a reduced dosage of ketoprofen (0."( The interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs.
Hara, S; Motoishi, K; Naito, Y; Narita, T; Sato, R; Tani, K, 2007
)
0.34
"The purpose of the present study was to develop the meloxicam transdermal dosage form."( The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel.
Chang, JS; Huang, YB; Tsai, YH; Wu, PC, 2007
)
0.34
" The objective of this study is to investigate MEL dosage regimens on COX-1, COX-2, and prostaglandin dehydrogenase (PGDH) expression in ovine intrauterine and fetal tissues."( Dose-dependent effects of meloxicam administration on cyclooxygenase-1 and cyclooxygenase-2 protein expression in intrauterine tissues and fetal tissues of a sheep model of preterm labor.
Adamson, SL; Challis, JR; Lye, SJ; Rac, VE; Rurak, D; Scott, CA; Small, C, 2007
)
0.34
"The objective of the present work was to improve the dissolution properties of the poorly water-soluble drug meloxicam by preparing solid dispersions with hydroxyethyl cellulose (HEC), mannitol and polyethylene glycol (PEG) 4000 and to develop a dosage form for geriatric population."( Solid dispersion of meloxicam: factorially designed dosage form for geriatric population.
Dahiya, S; Pathak, D; Pathak, K, 2008
)
0.35
" For meloxicam, we found 100% tolerance at a dosage of 15 mg, including the patient who showed a reaction to the celecoxib."( [Tolerance to celecoxib and meloxicam in patients with intolerance to nonsteroidal anti-inflammatory drugs].
Martínez-Cócera, C; Reig Rincón de Arellano, I; Rodríguez-Alvarez, M; Vázquez-Cortés, S; Vázquez-Fuertes, L, 2008
)
0.35
"It is believed that acute pain suppresses nervus vagus, thereby, influencing gastrointestinal secretion and motility, which are the two factors that are necessary for disintegration and dissolution of solid dosage forms."( Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi, A; Jamali, F, 2008
)
0.35
" The milk was collected 12h after dosing from cows which received meloxicam (0."( In-house reference materials: 5-hydroxyflunixin and meloxicam in cow milk-preparation and evaluation.
Jedziniak, P; Olejnik, M; Szprengier-Juszkiewicz, T, 2009
)
0.35
" The adequate condition for the chromatographic determination of these compounds in pharmaceutical dosage forms was established based on the different retention behaviors of the species."( Determination of pKa values of nonsteroidal antiinflammatory drug-oxicams by RP-HPLC and their analysis in pharmaceutical dosage forms.
Alsancak, G; Demiralay, EC; Ozkan, SA, 2009
)
0.35
" The model offers an in silico method to support an EHC hypothesis using standard pharmacokinetic data and might help to guide dosing recommendations of compounds undergoing EHC."( A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Kloft, C; Lehr, T; Schaefer, HG; Staab, A; Tillmann, C; Trommeshauser, D, 2009
)
0.35
"To observe the clinical effect of Wenhua Juanbi Recipe (WJR) in treating rheumatoid arthritis (RA), its effects in reducing the dosage of Western medicine used and stabilizing condition of disease, as well as its influences on peripheral blood levels of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and anti-cyclic citrullinated peptide antibody (anti-CCP), for the sake of exploring its preliminary acting mechanism."( [Effects of wenhua juanbi recipe on TNF-alpha and IL-1beta in peripheral blood of rheumatoid arthritis patients].
Liu, XD; Ye, LH; Zhang, JL, 2009
)
0.35
"The objectives of this study were to establish dose-response and blood concentration-response relationships for robenacoxib, a novel nonsteroidal anti-inflammatory drug with selectivity for inhibition of the cyclooxygenase (COX)-2 isoenzyme, in a canine model of synovitis."( Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
Jung, M; King, JN; Lees, P; Schmid, VB; Seewald, W; Spreng, DE, 2010
)
0.36
"The objectives of these investigations were: first, to describe the pharmacokinetic properties of meloxicam in cats following single and multiple oral administration and secondly, to simulate different oral dosage regimes for meloxicam in cats after multiple dose administration to illustrate and evaluate those dosage regimes for the alleviation of inflammation and pain in cats."( Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats.
Jöns, O; Kloft, C; Lehr, T; Narbe, R; Staab, A, 2010
)
0.36
"5 h and 1 h after administration of BCD-meloxicam orally than those of unmodified meloxicam (both dosed at 10 mg/kg)."( Influence on analgesic activity and serum levels after meloxicam complexation with beta-cyclodextrin in mice and rats.
Dolezal, T; Janovský, M; Krsiak, M; Procháizková, M; Slíva, J, 2010
)
0.36
" To assess potential toxicity, 4 iguanas were given meloxicam at a dosage of 1 or 5 mg/kg, PO, every 24 hours for 12 days, and results of histologic examination were compared with results for another 4 iguanas given a single dose of meloxicam (0."( Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana).
Barron, GH; Budsberg, SC; Divers, SJ; Hernandez, SM; Koch, TF; McBride, M; Papich, M; Perpinan, D; Pethel, M; Stedman, NL, 2010
)
0.36
" Our results indicate that the use of meloxicam or flunixin in accordance with the recommended dosage regimen in cattle do not have a clinically significant influence on apoptosis of peripheral blood T cells."( Evaluation of the influence of meloxicam and flunixin meglumine on the apoptosis of peripheral blood CD4+ and CD8+ T cells in calves.
Jakubowski, P; Jaroszewski, JJ; Markiewicz, W; Maślanka, T, 2010
)
0.36
" Palatability and accuracy of dosing were also assessed."( Clinical evaluation of meloxicam versus ketoprofen in cats suffering from painful acute locomotor disorders.
Grant, D; Johnston, L; Letellier, IM; Morton, CM; Narbe, R, 2011
)
0.37
" Flunixin meglumine at the given dosage (2."( Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice.
Blankenship-Paris, TL; Clark, JA; Goulding, DR; King-Herbert, AP; Kissling, GE; Travlos, GS; Tubbs, JT, 2011
)
0.37
"Response surface methodology (RSM) was used to develop and optimize the mesomorphic phase formulation for a meloxicam transdermal dosage form."( Formulation optimization of transdermal meloxicam potassium-loaded mesomorphic phases containing ethanol, oleic acid and mixture surfactant using the statistical experimental design methodology.
Huang, CT; Huang, YB; Tsai, CH; Tsai, YH; Tsou, HY; Wu, PC, 2011
)
0.37
"Two simple and inexpensive UV spectrophotometric methods were developed for the quantification and dissolution studies of meloxicam in tablet dosage forms."( Dissolution studies and quantification of meloxicam in tablet dosage form by spectrophotometry.
Boddu, R; Induri, M; Kunda, PR; Mantripragada, BR; Nannapaneni, DT; Yejella, RP, 2012
)
0.38
" An oral dosage form of meloxicam with enhanced aqueous solubility is desired to enable a faster onset of action and its use for mild-to-medium-level acute pain relief."( Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.
Cheney, ML; Hanna, M; Sanchez-Ramos, JR; Sava, V; Shan, N; Song, S; Weyna, DR; Zaworotko, MJ, 2012
)
0.38
" Dosage regimens used for many therapeutic drugs have been extrapolated from other ruminants; however, the pharmacokinetics, in camelids, may differ from those of other species."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
" These data suggest that a single dosage of oral meloxicam at 1 mg/kg could potentially maintain therapeutic concentrations in plasma for up to 3 days in adult llamas."( Bioavailability and pharmacokinetics of oral meloxicam in llamas.
Coetzee, JF; Kreuder, AJ; KuKanich, B; Layman, LL; Plummer, PJ; Schleining, JA; Wulf, LW, 2012
)
0.38
" 18-fold reduction of AUC(0-4) for orally dosed crystalline MEL (1."( Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
Inoue, R; Ochi, M; Onoue, S; Yamada, S; Yamauchi, Y, 2013
)
0.39
"Buprenorphine is commonly used as (part of) postoperative analgesic treatment with dosage dependent side-effects such as pica behaviour."( Optimizing the dosing interval of buprenorphine in a multimodal postoperative analgesic strategy in the rat: minimizing side-effects without affecting weight gain and food intake.
Arndt, SS; Hellebrekers, LJ; Mitsogiannis, MD; Schaap, MW; Uilenreef, JJ; van 't Klooster, JG, 2012
)
0.38
" En résumé, l'application de S-kétamine à un dosage correspondant à 60% de celui de la kétamine racémique produit une anesthésie similaire."( Racemic ketamine in comparison to S-ketamine in combination with azaperone and butorphanol for castration of pigs.
Bettschart-Wolfensberger, R; Flaherty, D; Hässig, M; Ringer, SK; Stauffer, S, 2013
)
0.39
" Results of this study suggest that the current recommended once-daily dosing interval of oral meloxicam is unlikely to maintain plasma concentrations anticipated to be therapeutic in either RTH or GHO, and practical dosing options are questionable for this nonsteriodal anti-inflammatory drug in these raptor species."( Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Boothe, DM; Gamble, KC; Lacasse, C, 2013
)
0.39
" This study indicates that eutherians such as rats or dogs serve as inadequate models for dosage extrapolation of this drug to marsupials due to differences in hepatic turnover rate."( In vitro hepatic microsomal metabolism of meloxicam in koalas (Phascolarctos cinereus), brushtail possums (Trichosurus vulpecula), ringtail possums (Pseudocheirus peregrinus), rats (Rattus norvegicus) and dogs (Canis lupus familiaris).
Govendir, M; Higgins, DP; Kimble, B; Krockenberger, MB; Li, KM; Valtchev, P, 2014
)
0.4
" Sustained-release (SR) formulations of analgesics maintain plasma levels that should be sufficient to provide sustained analgesia yet require less frequent dosing and thus less handling of and stress to the animals."( Pharmacokinetics of sustained-release analgesics in mice.
Dorsey, K; Gustafson, DL; Hansen, RJ; Kang, S; Kendall, LV; Lunghofer, PJ, 2014
)
0.4
" Minimal information has been published regarding appropriate dosing in nonhuman primates."( Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).
Bauer, C; Frost, P; Kirschner, S, 2014
)
0.4
"1 mg/kg appears safe for use in this species, but caution in repeated dosing must be used, due to the prolonged elimination, until multi-dose pharmacokinetic studies are determined."( Pharmacokinetics of single dose oral meloxicam in bottlenose dolphins (Tursiops truncatus).
Jensen, ED; Meegan, JM; Nollens, HH; Papich, MG; Schmitt, TL; Simeone, CA; Smith, CR, 2014
)
0.4
" The early systemic exposure to Mel and hence the rapid onset of pharmacological action is limited by its poor water solubility; a situation which may be more pronounced during acute pain episode because of reduced gastric motility that affects disintegration and dissolution of solid dosage forms."( Particle engineering/different film approaches for earlier absorption of meloxicam.
El-Bayomi, T; El-Nabarawi, MA; El-Setouhy, DA; Farid, M, 2016
)
0.43
"Data on reptile analgesia are scarce for nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids and almost completely lacking in sea turtles, even though emergencies requiring correct pain management are very frequent in their rehabilitative medicine; therefore, dosage regimens extrapolated from other species involve the risk of clinical failure and damage to the animals."( Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration.
Cavaliere, L; Crescenzo, G; Di Bello, A; Freggi, D; Lai, OR; Marzano, G; Soloperto, S, 2015
)
0.42
"Meloxicam administered orally at the dosage used in this study caused no apparent negative changes in several renal, gastrointestinal, or hemostatic variables in healthy Hispaniolan Amazon parrots."( Renal, gastrointestinal, and hemostatic effects of oral administration of meloxicam to Hispaniolan Amazon parrots (Amazona ventralis).
Dijkstra, B; Gustavsen, K; Guzman, DS; Hass, C; Kass, PH; Owens, SD; Paul-Murphy, JR, 2015
)
0.42
" On the basis of these results, meloxicam administered at the dosage used in this study protocol does not appear to cause renal disease in African grey parrots."( Effects of Meloxicam on Hematologic and Plasma Biochemical Analyte Values and Results of Histologic Examination of Kidney Biopsy Specimens of African Grey Parrots (Psittacus erithacus).
Ardiaca, M; Juan-Sallés, C; Montesinos, A; Tesouro, MA, 2015
)
0.42
" The results suggest that these mats may be a good candidate for fast dissolving drug delivery systems of bitter drugs to increase the palatability of dosage forms."( Fast releasing oral electrospun PVP/CD nanofiber mats of taste-masked meloxicam.
Akkaramongkolporn, P; Kaomongkolgit, R; Ngawhirunpat, T; Opanasopit, P; Rojanarata, T; Samprasit, W, 2015
)
0.42
" The present study investigated the meloxicam in different dosage forms (powder, spray, gel)."( [Investigation of permeability of intranasal formulations using Side-Bi-Side horizontal diffusion cell].
Ambrus, R; Szabóné, RP, 2015
)
0.42
" Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management."( Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Ambrus, R; Bartos, C; Budai-Szűcs, M; Csányi, E; Gáspár, R; Horváth, T; Márki, Á; Seres, AB; Sipos, P; Szabó-Révész, P; Sztojkov-Ivanov, A, 2015
)
0.42
" Computer simulations of disease states can be employed to optimize drug release from dosage forms to overcome the reported shortfalls in the drug absorption."( Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions.
Aghazadeh-Habashi, A; Almukainzi, M; Jamali, F; Löbenberg, R, 2016
)
0.43
" Further studies are warranted to determine the effective plasma concentration of meloxicam in turtles and, consequently, the dosage regimen."( Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations.
Catanzaro, A; Deli, G; della Rocca, G; Di Salvo, A; Giorgi, M, 2016
)
0.43
" Further studies are needed to evaluate the effects of the drug volume administered and fasting status when oral dosing is used."( Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber).
Carpenter, JW; KuKanich, B; Lindemann, DM, 2016
)
0.43
" According to the results, the produced samples could be applied as a basic material (micronized MEL) and intermediate product (micronized and nanonized MEL with PVA) for the design of dosage forms."( The Effect of an Optimized Wet Milling Technology on the Crystallinity, Morphology and Dissolution Properties of Micro- and Nanonized Meloxicam.
Ambrus, R; Bartos, C; Jójárt-Laczkovich, O; Katona, G; Szabó-Révész, P, 2016
)
0.43
" The present study demonstrated an effective method for the preparation of suitable dosage form of MLX with improved solubility and onset of action."( Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
Dehghani, H; Homayouni, A; Taheri, A, 2017
)
0.46
"Postoperative analgesia in laboratory rats is complicated by the frequent handling associated with common analgesic dosing requirements."( Postoperative Analgesia Due to Sustained-Release Buprenorphine, Sustained-Release Meloxicam, and Carprofen Gel in a Model of Incisional Pain in Rats (Rattus norvegicus).
Adams, SC; Felt, SA; Jampachaisri, K; Pacharinsak, C; Seymour, TL; Yeomans, DC, 2016
)
0.43
" These findings suggest that the current meloxicam dosing guidelines may be subtherapeutic for prairie dogs."( Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (
Cary, CD; Gallardo-Romero, NF; Hutson, CL; Lathrop, GW; Lukovsky-Akhsanov, NL; Morgan, CN; Ostergaard, SD; Powell, N; Tansey, CM; Taylor, WD, 2017
)
0.46
" The quality by design (QbD) approach for the development of pharmaceutical products ensured high quality of the dosage form and good understanding of the preparation process."( Development of oral lyophilisates containing meloxicam nanocrystals using QbD approach.
Ambrus, R; Bogdan, C; Chvatal, A; Iurian, S; Leucuța, SE; Moldovan, M; Szabó-Révész, P; Tomuță, I, 2017
)
0.46
" These results suggest that electospun films from EtOH system may be a good candidate for fast-dissolving drug delivery systems to increase palatability of dosage forms."( Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam.
Akkaramongkolporn, P; Kaomongkolgit, R; Opanasopit, P; Samprasit, W, 2018
)
0.48
" This study determined the pharmacokinetics of meloxicam in domestic chickens (n = 8) after oral dosing at 1 mg/kg q12h for a total of 9 doses (5 days)."( Pharmacokinetics and Egg Residues of Meloxicam After Multiple Day Oral Dosing in Domestic Chickens.
Bailey, J; Cox, SK; Gerhardt, L; Gordon, K; Souza, MJ; White, M, 2018
)
0.48
"2 mg/kg appears safe for use in male Malayan flying foxes, but due to rapid elimination, frequent dosing may be required to maintain plasma concentrations within a therapeutic range."( PHARMACOKINETICS OF MELOXICAM FOLLOWING A SINGLE ORAL DOSE IN MALAYAN FLYING FOXES ( PTEROPUS VAMPYRUS).
Cox, S; Goodnight, AL, 2018
)
0.48
"The dissolution rate of Mel from the poly(vinyl alcohol) stabilized nanosuspension justified its applicability in the design of innovative per oral dosage form (capsule) in order to ensure/give a rapid analgesia."( Optimization of a combined wet milling process in order to produce poly(vinyl alcohol) stabilized nanosuspension.
Ambrus, R; Bartos, C; Bocsik, A; Budai-Szűcs, M; Deli, MA; Gróf, I; Jójárt-Laczkovich, O; Katona, G; Szabó-Révész, P, 2018
)
0.48
"Gastric resident dosage forms have been used successfully in farm animals for the delivery of a variety of drugs helping address the challenge of extended dosing."( Scalable Gastric Resident Systems for Veterinary Application.
Bajpayee, A; Bensel, T; Cleveland, C; Collins, J; Hayward, A; Hua, T; Kirtane, AR; Langer, R; Lee, YL; Lopes, A; Mazdiyasni, H; McDonnell, S; Rogner, J; Traverso, G; Wahane, A, 2018
)
0.48
" Ovariohysterectomy was associated with 2 d of postoperative pain, and all 3 buprenorphine dosing strategies and both doses of meloxicam demonstrated varying amounts of analgesia."( Evaluation of Analgesic Efficacy of Meloxicam and 2 Formulations of Buprenorphine after Laparotomy in Female Sprague-Dawley Rats.
Adams, CR; Fortman, JD; Goldman, JL; Nunamaker, EA, 2018
)
0.48
" Meloxicam was dosed at 1 mg/kg of body weight, and an empty gel capsule served as a placebo."( Meloxicam administration either prior to or after parturition: Effects on behavior, health, and production in dairy cows.
Bewley, JM; Leslie, KE; Petersson-Wolfe, CS; Schramm, HH; Swartz, TH; Wood, CM, 2018
)
0.48
" This study demonstrates that a single intramuscular injection of meloxicam at a dosage of 5 mg/kg does not cause acute toxicity in goldfish."( ABSENCE OF ACUTE TOXICITY OF A SINGLE INTRAMUSCULAR INJECTION OF MELOXICAM IN GOLDFISH ( CARASSIUS AURATUS AURATUS): A RANDOMIZED CONTROLLED TRIAL.
Lair, S; Larouche, CB; Limoges, MJ, 2018
)
0.48
"Meloxicam is commonly used in avian medicine to relieve pain and inflammation, but the recommended dosing frequency can be multiple times per day, which can contribute to stress during convalescence."( PHARMACOKINETICS OF A SUSTAINED-RELEASE FORMULATION OF MELOXICAM AFTER SUBCUTANEOUS ADMINISTRATION TO AMERICAN FLAMINGOS ( PHOENICOPTERUS RUBER).
Cox, SK; Sim, RR, 2018
)
0.48
" Although administration of meloxicam at a dosage of 1 mg/kg IM and PO daily for 1 week and 12 days, respectively, was not associated with adverse clinical effects in this population, further studies are needed to assess the efficacy and safety of the drug during prolonged treatment and the clinical relevance of its accumulation."( Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus).
Ardiaca, M; Bonvehí, C; Encinas, T; Gilabert, JA; Montesinos, A; Orós, J, 2019
)
0.51
"Granule formulation has different PK parameters compared to other oral formulations, which could enable this formulation to be used for different dosage regimens in order to reach a desired clinical effect or decrease the risk of adverse effects."( Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.
Mendoza, FJ; Perez-Ecija, A; Serrano-Rodriguez, JM, 2019
)
0.51
"15 mg/kg) in ≤6 hours after morphine dosing on postoperative day 1 and were evaluated for 24 hours."( Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial.
Du, W; Freyer, A; Mack, RJ; McCallum, SW; Rechberger, T, 2019
)
0.51
" Once-daily administration of meloxicam IV produced analgesic effect within 6-8 minutes postdose that was maintained over a 24-hour dosing interval."( Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial.
Du, W; Freyer, A; Mack, RJ; McCallum, SW; Rechberger, T, 2019
)
0.51
"The objectives of this work were to develop meloxicam based amorphous solid dispersion through electrospinning technique and evaluate the effect of the polymeric matrix on the physicochemical properties of the fibers and the downstream processing ability to orodispersible dosage forms."( Electrospun amorphous solid dispersions of meloxicam: Influence of polymer type and downstream processing to orodispersible dosage forms.
Balogh, A; Bogdan, C; Borbás, E; Casian, T; Démuth, B; Farkas, A; Farkas, B; Ilyés, K; Iurian, S; Marosi, G; Nagy, ZK; Rapi, Z; Știufiuc, R; Toma, V; Tomuță, I, 2019
)
0.51
" In phases II and III geese were treated orally at the same dosage for the collection of blood and tissue samples, respectively."( Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese.
Giorgi, M; Lisowski, A; Owen, H; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
" In conclusion, pharmacokinetic parameters of meloxicam are not significantly altered by lactation for either the IV or IM routes of administration and this drug does not require a different dosage regimen for lactating animals."( Impact of lactation on pharmacokinetics of meloxicam in goats.
Giorgi, M; Kim, TW; Lisowski, A; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2020
)
0.56
" The goal of this study was to compare the pharmacokinetics of a single subcutaneous dose of a sustained-release formulation of meloxicam (Melox-SR) with those of oral (Melox-PO) and standard subcutaneous (Melox-SC) formulations dosed every 24 h for 3 consecutive days."( Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.
Kendall, LV; Kirschner, SM; Smith, BJ, 2020
)
0.56
" Concentrations were adapted to comparable relations of the recommended dosage for systemic application."( Nonsteroidal anti-inflammatory drugs affect the mammary epithelial barrier during inflammation.
Bruckmaier, RM; Sintes, GF; Wellnitz, O, 2020
)
0.56
" However, its oral dosage form can cause many adverse gastrointestinal effects."( Deformable Liposomal Hydrogel for Dermal and Transdermal Delivery of Meloxicam.
Michniak-Kohn, B; Osmałek, T; Zhang, ZJ, 2020
)
0.56
" Every 3 weeks, the dosage of the drug was increased by 50 mg to 300 mg per day under the control of the level of serum uric acid (sUA)."( [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout].
Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020
)
0.56
" Therefore, the oral dosing interval of meloxicam may be greater for Wyandotte hens."( Breed differences in the pharmacokinetics of orally administered meloxicam in domestic chickens (
Bergman, JB; Condon, M; Cox, SK; Davis, R; Fortner, C; Gerhardt, LE; Shannon, L; Souza, MJ, 2021
)
0.62
" Antibiotic therapy was set based on the antibiogram, and marbofloxacin was chosen at a dosage of 10 mg/kg subcutaneously (SC) once per day (SID)."( Klebsiella sp.-related infectious spondylitis in a bearded dragon (Pogona vitticeps).
Bertocchi, M; Di Ianni, F; Gerosa, S; Moggia, E; Pelizzone, I; Vetere, A, 2021
)
0.62
" We conclude that meloxicam has potential application for pain management in mice but that the dosage must be adjusted carefully according to the experimental procedures."( Administration of meloxicam to improve the welfare of mice in research: a systematic review (2000 - 2020).
Alemán-Laporte, J; Antiorio, ATFB; Cintra, L; de Freitas, APP; Mori, CMC; Yamamoto, PK, 2022
)
0.72
"Backyard poultry are commonly treated in veterinary hospitals; however, there is limited information regarding appropriate dosing of medications and withdrawal times for eggs."( Pharmacokinetics and Egg Residues of Oral Meloxicam in Bantam Cochin Chickens.
Bergman, J; Cox, S; Gerhardt, L; Harvill, L; Singleton, S; Souza, MJ; Stilz, CR, 2022
)
0.72
" The indication(s) for its use and the dosage prescribed were within the manufacturer's recommendations for Australian veterinarians."( Acute kidney injury in 18 cats after subcutaneous meloxicam and an update on non-steroidal anti-inflammatory drug usage in feline patients in Australia.
King, T; Korman, R; Leister, E; Malik, R; Wun, MK, 2023
)
0.91
" It reduces opioid use after surgery and manages pain better than BVC alone over 72 h, and overcomes surgical site inflammation with a new synergistic mode of action that combines BVC with a low dosage of MLX."( Manipulation and Processing of Spectral Signals for the Assay of the Newly Authorized Mixture of Bupivacaine/Meloxicam Using Fully Green Solvents and a Comparative Green Evaluation Supporting the Greenness and Sustainability of the Developed Smart Spectro
Bahgat, EA; Eissa, MS; Hashem, H; Kamel, EB; Saleh, H, 2023
)
0.91
" The present study aimed to determine the depletion profiles of meloxicam in eggs with multiple oral administration under 2 different dosing regimens and to further recommend reasonable withdrawal intervals (WDIs)."( Egg residue and depletion of meloxicam in Jing Hong laying hens following multiple oral doses.
Chen, JC; Dai, Y; Duan, MH; Gao, L; Li, HT; Li, XP; Li, ZE; Shao, HT; Yang, F; Zhang, M, 2023
)
0.91
"MLX-emulgel may be a potential candidate for translating in to a clinically viable dosage form in the management of knee OA."( Meloxicam emulgel potently suppressed cartilage degradation in knee osteoarthritis: Optimization, formulation, industrial scalability and pharmacodynamic analysis.
Jyothi, VGS; Khatri, DK; Kumar, R; Madan, J; Singh, SB; Veerabomma, H, 2023
)
0.91
" Comparative studies on dose-response effects of firocoxib and meloxicam in lambs following the procedures are required."( Pharmacokinetics and effect on renal function and average daily gain in lambs after castration and tail docking, of firocoxib and meloxicam.
Dukkipati, V; Hunt, H; Kongara, K; Purchas, G; Speed, D; Venkatachalam, D; Ward, N, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antirheumatic drugA drug used to treat rheumatoid arthritis.
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzothiazine
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
1,3-thiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Meloxicam Action Pathway2967

Protein Targets (51)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency28.80790.007215.758889.3584AID1224835; AID588342
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency1.19863.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.95210.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346859
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency26.98250.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency54.48270.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency30.85220.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743040; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency34.62250.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.77120.000417.946075.1148AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.11220.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency43.23050.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.25490.001530.607315,848.9004AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency45.94640.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.69620.000229.305416,493.5996AID1259244; AID743069; AID743075; AID743079
GVesicular stomatitis virusPotency10.96400.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency55.07550.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.94100.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency32.76560.023723.228263.5986AID743222; AID743223
alpha-galactosidaseHomo sapiens (human)Potency44.66844.466818.391635.4813AID2107
aryl hydrocarbon receptorHomo sapiens (human)Potency61.13060.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency25.00420.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency21.872419.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.75030.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency35.82220.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency45.20950.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency15.85240.004611.374133.4983AID624296; AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency10.96400.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency76.95880.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency76.95880.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)77.50000.11007.190310.0000AID1473738
Glutathione reductase, mitochondrialHomo sapiens (human)Ki6.10000.80003.45006.1000AID1803039
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Ki57.90001.19105.12919.9410AID1802951
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)19.95560.00021.557410.0000AID1589006; AID161316; AID161468; AID161476; AID1720169; AID1854722; AID625243
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)8.55980.00010.995010.0000AID1589007; AID162326; AID162478; AID162494; AID1720170; AID1854723; AID625244
6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)Ki37.30000.01002.74508.3000AID1802944
Prostaglandin G/H synthase 2Mus musculus (house mouse)IC50 (µMol)0.15140.00050.40086.2000AID1330179
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (197)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
pentose-phosphate shunt6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose-phosphate shunt, oxidative branch6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose biosynthetic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
D-gluconate catabolic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
phosphogluconate dehydrogenase (decarboxylating) activity6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
NADP binding6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
nucleus6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
extracellular exosome6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (230)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1720173Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO generation at 10 to 100 uM pretreated for 24 hrs measured after 10 mins by Griess reagent based assay
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1720185Ulcerogenic activity in Kunming mouse assessed as infiltration of inflammatory cells in stomach mucosa at 700 umol/kg, po administered as single dose measured at 7 hrs post ligation by light microscopic analysis
AID183493Antiinflammatory activity in the carrageenan paw edema model at a dose of 30 mg/kg. 1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID1529187Binding affinity to human serum albumin assessed as change in dissociation constant pKa2 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID160404Inhibition of human Prostaglandin G/H synthase 2 at 10 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID543965Inhibition of TxB2 production in human blood at 15 mg, po measured up to 48 hrs by enzyme immunoassay pretreated with itraconazole at 200 mg, po qd for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID161836Inhibition of human Prostaglandin G/H synthase 1 at 1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID161320Inhibitory activity against Prostaglandin G/H synthase 1 in Microsomal assay at dose 10 ug/ml1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID1330178Inhibition of sheep seminal vesicle COX-1 assessed as reduction in oxygen consumption using arachidonic acid as substrate incubated for 12 mins followed by substrate addition measured for 2 mins2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID161318Inhibitory activity against Prostaglandin G/H synthase 1 in Microsomal assay at dose 0.1 ug/mL1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID161835Inhibition of human Prostaglandin G/H synthase 1 at 0.1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID161682Highest percent inhibition against Prostaglandin G/H synthase 1 observed on IC50 curve; Range 80-90%1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1733247Antialzheimer activity against AlCl3-induced Sprague-Dawley rat assessed as reduction in hippocampal neuronal degeneration at 5 mg/kg, po after 28 days by H and E staining based microscopic method2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID543976Protein binding in human plasma at 15 mg, po after 5 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID161476In vitro for its inhibitory activity against human whole blood Prostaglandin G/H synthase 11999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1594427Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX2 mRNA expression at 50 uM preincubated for 30 mins followed by LPS-stimulation and measured after 18 hrs by QuantiFast SYBR Green dye based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Further sesquiterpenoids from the rhizomes of Homalomena occulta and their anti-inflammatory activity.
AID1720187Anti-inflammatory activity against carrageenan-induced Sprague-Dawley rat model assessed as decrease of PGE2 expression level at 150 uM/kg, po dosed 1 hr post after carrageenan challenge measured after 8 hrs by ELISA assay
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID543968Half life in human at 15 mg, po2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID543979Inhibition of TxB2 production in human blood at 15 mg, po after 5 hrs by enzyme immunoassay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID162494In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 21999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1733243Antialzheimer activity against AlCl3-induced Sprague-Dawley rat assessed as reduction in brain LPO activity at 5 mg/kg, po after 28 days by UV-VIS spectrophotometric method2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID543977Protein binding in human at 15 mg, po pretreated with voriconazole at 400 mg, po every 12 hrs for 1 day and 200, po mg every 12 hrs for one additional day measured after 5 hrs last post dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1720183Ulcerogenic activity in Kunming mouse assessed as gastric lesion at 700 umol/kg, po administered as single dose measured at 7 hrs post ligation by microscopic analysis
AID1712996Selectivity for COX-2 (unknown origin) over COX-1 (unknown origin)2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1733241Toxicity in AlCl3-induced Sprague-Dawley rat assessed as reduction in total protein level at 5 mg/kg, po after 28 days by automated analyser2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1720171Selectivity index, ratio of IC50 for human recombinant COX1 to IC50 for human recombinant COX2 using arachidonic acid as substrate preincubated for 10 mins measured after substrate addition by microplate reader based enzyme immunoassay
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID543983Inhibition of TxB2 production in human blood at 15 mg, po after 48 hrs by enzyme immunoassay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID543959Inhibition of TxB2 production in human blood at 15 mg, po after 48 hrs by enzyme immunoassay pretreated with itraconazole at 200 mg, po qd for 4 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID160402Inhibition of human Prostaglandin G/H synthase 2 at 0.1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID161837Inhibition of human Prostaglandin G/H synthase 1 at 10 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1330179Inhibition of mouse COX-2 expressed in baculovirus infected Sf21 insect cells assessed as reduction in oxygen consumption using arachidonic acid as substrate incubated for 12 mins followed by substrate addition measured for 2 mins2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1656367Covalent protein binding in human liver microsomes assessed per mg protein at 50 uM after 60 mins in presence of NADPH by LC-MS/MS method2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Designing around Structural Alerts in Drug Discovery.
AID569058Antiinflammatory activity against Wistar-Bratislava albino rat assessed as leukocyte count at 3.2 mg/kg, ip (Rbv = 4952.7+/-436.9 number/mm'3)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID569057Antiinflammatory activity against Wistar-Bratislava albino rat assessed as neutrophil count at 3.2 mg/kg, ip (Rbv = 55.6+/-1.32%)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1733245Antialzheimer activity against AlCl3-induced Sprague-Dawley rat assessed as change in brain SOD activity at 5 mg/kg, po after 28 days2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1720169Inhibition of human recombinant COX1 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate preincubated for 10 mins measured after substrate addition by microplate reader based enzyme immunoassay
AID773503Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 10 mg/kg, po after 2 hrs by pletismometric analysis relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and anti-inflammatory activity of three nitro chalcones.
AID1733248Toxicity in AlCl3-induced Sprague-Dawley rat assessed as intestine lesion index at 5 mg/kg, po after 28 days by H and E staining based microscopic method2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID1733216Toxicity in AlCl3-induced Sprague-Dawley rat assessed as stomach lesion index at 5 mg/kg, po after 28 days by H and E staining based microscopic method2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID569056Antiinflammatory activity against Wistar-Bratislava albino rat assessed as monocyte count at 3.2 mg/kg, ip (Rbv = 7.6+/-0.45%)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1733235Toxicity in AlCl3-induced Sprague-Dawley rat assessed as reduction in HGB level at 5 mg/kg, po after 28 days by automated haematology analyser2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1589007Inhibition of COX2 (unknown origin) assessed as suppression of PGG2 conversion to PGH2 incubated fro 2 mins by TMPD based colorimetric assay2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
COX-1/COX-2 inhibition activities and molecular docking study of newly designed and synthesized pyrrolo[3,4-c]pyrrole Mannich bases.
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID161319Inhibitory activity against Prostaglandin G/H synthase 1 in Microsomal assay at dose 1 ug/ml1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID1589006Inhibition of COX1 (unknown origin) assessed as suppression of PGG2 conversion to PGH2 incubated fro 2 mins by TMPD based colorimetric assay2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
COX-1/COX-2 inhibition activities and molecular docking study of newly designed and synthesized pyrrolo[3,4-c]pyrrole Mannich bases.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1733240Toxicity in AlCl3-induced Sprague-Dawley rat assessed as reduction in serum albumin level at 5 mg/kg, po after 28 days by automated analyser2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID773502Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 10 mg/kg, po after 3 to 7 hrs by pletismometric analysis relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and anti-inflammatory activity of three nitro chalcones.
AID543966AUC (0 to 72 hrs) in human at 15 mg, po2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1854722Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1720181Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced STAT3 phosphorylation at 10 to 100 uM incubated for 24 hrs by Western blot analysis
AID178663Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using preventive method; dose administered daily once2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID1733236Toxicity in AlCl3-induced Sprague-Dawley rat assessed as reduction in HCT level at 5 mg/kg, po after 28 days by automated haematology analyser2021Bioorganic & medicinal chemistry, 04-15, Volume: 36Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
AID229532Ratio of IC50 values at Cyclooxygenase-1 and Cyclooxygenase-21999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID543981Inhibition of TxB2 production in human blood at 15 mg, po after 12 hrs by enzyme immunoassay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID162329Inhibitory activity against Prostaglandin G/H synthase 2 in Microsomal assay at dose 1 ug/ml1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID543967Cmax in human at 15 mg, po2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID160403Inhibition of human Prostaglandin G/H synthase 2 at 1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID161316Concentration that caused a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 1 activity as measured by PGE-2 production.1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1720170Inhibition of human recombinant COX2 assessed as reduction in PGH2 formation using arachidonic acid as substrate preincubated for 10 mins measured after substrate addition by microplate reader based enzyme immunoassay
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID543969Tmax in human at 15 mg, po2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID543978Protein binding in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days measured after 5 hrs last post dose2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1589008Ratio of IC50 for inhibition of COX2 (unknown origin) to IC50 for inhibition of COX1 (unknown origin)2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
COX-1/COX-2 inhibition activities and molecular docking study of newly designed and synthesized pyrrolo[3,4-c]pyrrole Mannich bases.
AID543980Inhibition of TxB2 production in human blood at 15 mg, po after 8 hrs by enzyme immunoassay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID162328Inhibitory activity against Prostaglandin G/H synthase 2 in Microsomal assay at dose 0.1 ug/mL1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID161468Concentration of drug that causes a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 1 activity as measured by PGE-2 production (''++'' indicates 80-90% inhibition)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1720174Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced TNFalpha production at 100 uM measured after 24 hrs by ELISA
AID162478Concentration of drug that causes a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 2 activity as measured by PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID569055Antiinflammatory activity against Wistar-Bratislava albino rat assessed as lymphocyte count at 3.2 mg/kg, ip (Rbv = 37+/-2.2%)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole.
AID162330Inhibitory activity against Prostaglandin G/H synthase 2 in Microsomal assay at dose 10 ug/ml1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID160240Highest percent inhibition against Prostaglandin G/H synthase 2 observed on IC50 curve; Range 80-90%1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1720180Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NF-kappaB p65 phosphorylation at 10 to 100 uM incubated for 24 hrs by Western blot analysis
AID1193500Thermodynamic equilibrium solubility, log S of the compound2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1854723Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1316145Antiinflammatory activity in MSU-induced beagle dog acute synovitis model assessed as prevention of inflammation-driven lameness at 0.2 mg/kg, po administered once a week 3 hrs post MSU injection measured after 6 hrs post last dose2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
AID543964Fraction unbound in human plasma at 15 mg, po2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1720182Acute toxicity in Kunming mouse administered orally as single dose measured at day 7
AID162326Concentration that caused a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 2 activity as measured by PGE-2 production.1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
AID543982Inhibition of TxB2 production in human blood at 15 mg, po after 24 hrs by enzyme immunoassay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1802944In Vitro Assay from Article 10.3109/14756360903257900: \\Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.\\2010Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 25, Issue:4
Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.
AID1802951In Vitro Inhibition Assay from Article 10.3109/14756360903489581: \\Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.\\2010Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.
AID1803039Activity Assay from Article 10.3109/14756366.2011.572879: \\In vitro effects of some drugs on human erythrocyte glutathione reductase.\\2012Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1
In vitro effects of some drugs on human erythrocyte glutathione reductase.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1345206Human COX-2 (Cyclooxygenase)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1345284Human COX-1 (Cyclooxygenase)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,654)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's121 (7.32)18.2507
2000's524 (31.68)29.6817
2010's751 (45.41)24.3611
2020's258 (15.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.52 (24.57)
Research Supply Index7.67 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index198.12 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (106.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials396 (22.77%)5.53%
Reviews83 (4.77%)6.00%
Case Studies98 (5.64%)4.05%
Observational5 (0.29%)0.25%
Other1,157 (66.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]